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9SUMMARY
Usher syndrome type 3 (USH3) is an autosomal recessive disorder characterized by progressive
hearing loss, severe retinal degeneration, and variably present vestibular dysfunction. USH3
comprises about 40% of the Finnish USH population, and thereby it belongs to the Finnish
disease heritage (Pakarinen et al., 1995a). After the preliminary localization of USH3 to a 5-cM
interval on chromosome 3q21-q25 by Sankila et al. in 1995, the molecular analysis, by means of
genetic and physical mapping, was initiated. Yeast and bacterial artificial chromosome (YAC and
BAC) clones covering the region of interest were placed in contiguous series, and the overlaps
between different clones were established on the basis of shared sequence tagged sites (STSs) and
expressed sequence tags (ESTs) using primers for amplification. Based on the physical map, the
positional candidate genes PFN2, encoding human profilin-2, and KIAA0001, were assigned to
the critical USH3 interval. By use of an orthologous EST sequence, a putative mouse homologue,
Pfn2, was mapped on mouse chromosome 3 suggesting localization for the mouse homologue of
USH3 . The identification of novel polymorphic markers, and the analyses of linkage
disequilibrium and haplotypes in 32 USH3 families, eventually led to the refined localization of
USH3 to a 250-kb genomic interval. Once the USH3 region was cloned in manageable ordered
pieces, it was possible to determine its complete DNA sequence.
The 149-kb and 207-kb genomic sequence contigs across the USH3  region were
constructed by shotgun cloning and sequencing, followed by contig assembling, of three BAC
clones. Later, as the haplotypes in two USH3 chromosomes indicated a novel centromeric border
at marker 107G19CA7, the sequence analysis was focused on the 207-kb genomic contig defined
by the new marker. The subsequent computational sequence annotation revealed several human
and orthologous mouse and rat ESTs, as well as two previously identified protein encoding genes,
KIAA0001 and H963. In addition, two novel genes, NOPAR and its splice variant NOPAR2, as
well as an unprocessed pseudogene, UCRP, were constructed by RT-PCR and RACE
experiments. All these genes were examined in patients and excluded as USH3.
As attempts to find additional transcripts in the 207-kb region did not reveal new
information, the analysis was extended towards the next centromeric marker 25B8CA2. A retina-
derived EST was identified, and a novel gene encoding a predicted 120 amino acid
transmembrane protein with no homology to known proteins was constructed from the extended
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133-kb USH3 region. Three disease causing mutations were identified in the coding region of the
USH3 gene in affected individuals. The major Finnish founder mutation is a Y100X nonsense
mutation, which is present in 94% of the USH3 patients analyzed. A second mutation, M44K,
was identified in two Finnish families, in which four patients were compound heterozygous for
Y100X and a missense mutation M44K. Finally, a homozygous 3-bp deletion that results in the
amino acid substitution of one methionine for isoleucine and leucine was detected in an Italian
family. One carrier of the Y100X mutation was identified among 200 Finnish unrelated controls.
The identification of the USH3 gene and the study of the mutated gene product will
provide novel insight into the understanding of the biological basis of deafness and blindness. It
remains to be elucidated by in vitro and in vivo functional analyses, how the mutations cause the
defects of the sensory cells in the inner ear and the retina. At present, the use of mutation
detection will be useful for earlier diagnosis of the disease. Genetic testing will enable
presymptomatic and prenatal diagnosis in those families who wish it. Moreover, carrier diagnosis
can be offered for individuals whose family members are known to be associated with USH3. It
will also permit a more accurate genetic counseling to be offered to families. Eventually, it may
allow the development of new specific therapies.
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INTRODUCTION
A remarkable progress has been made in identification of deafness genes during the past years.
To date, over 400 syndromes including deafness have been listed, and 77 loci for nonsyndromic
deafness have been reported (On line Mendelian Inheritance of Man; Hereditary Hearing Loss
Homepage). Already over 90 different mouse genes that are known to affect the inner ear have
been identified, and around 20 mouse mutants with inner ear defects provide models for human
inherited disorders including hearing loss (Steel and Kros, 2001). Many of the human genes for
dominant and recessive forms of nonsyndromic and syndromic hearing loss encode proteins,
which localize in specialized regions and cell types of the cochlea, and are involved for example
in ion homeostasis, in the development of the auditory and vestibular systems, and in
transcriptional events (Gillespie and Walker, 2001; Steel and Kros, 2001).
Usher syndrome (USH) is a recessively inherited disorder, which combines
simultaneously both hearing impairment and progressive loss of vision due to retinitis pigmentosa
(RP). Based on the clinical features, the syndrome has been divided into three subtypes: USH1,
USH2, and USH3 (Davenport and Omenn, 1977). Type 1 (USH1) is characterized by a
congenital severe to profound and preverbal deafness, an absent vestibular function, and an early
onset of retinal deterioration. Type 2 (USH2) has a milder congenital hearing loss, which
deteriorates very slowly, and a later onset of retinal degeneration. Balance functions are normal.
The existence of a third distinct clinical type of USH, USH3, with a progressive postverbal
hearing loss and variable vestibular function, was not generally accepted (Smith et al., 1994),
until Sankila et al. (1995) assigned the USH3 locus on chromosome 3q21-q25 by linkage. In
addition, in the study by Pakarinen et al. (1995a), the USH3 phenotype was shown to be the
major USH type in Finland comprising about 40% of USH cases, while it was thought to be the
rarest clinical type in other countries (Davenport and Omenn, 1977).
Among USH, at least ten different loci have been detected, and six genes have been
identified, for USH1B (Weil et al., 1995), for USH1C (Bitner-Glindzicz et al., 2000; Verpy et al.,
2000), for USH1D (Bolz et al., 2001; Bork et al., 2001), for USH1F (Ahmed et al., 2001;
Alagramam et al., 2001b), for USH2A (Eudy et al., 1998), and for USH3, which we identified in
this study by positional cloning methods. At least three USH genes, USH1B, USH1D, and
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USH2A, underlie other isolated auditory or visual sensory defects as well (Bork et al., 2001; Liu
et al., 1997b; Liu et al., 1997d; Rivolta et al., 2000).
The mutated USH genes cause defects, especially in the organ of Corti, where severe
degeneration is observed. Although the specific expression patterns for some of the USH proteins
in the cochlea and the retina are known, their exact molecular pathways in these organs remains
to be elucidated. In this regard, mouse mutants have given important information in the study of
molecular pathogenesis of the disease. Similarities between hereditary deafness in humans and
mice suggest that mice are important animal models for human deafness. An example is the
characterization of the myosin VIIA gene (MYO7A), which is involved in mouse shaker-1 (sh-1)
deafness and in human USH1B (Gibson et al., 1995; Weil et al., 1995). Based on the studies with
the mutant sh-1 mouse, the actin-mediated organization and function of hair cells and
photoreceptors, such as assembly of the stereocilia bundles, endocytosis and membrane recycling,
protein transport, neurotransmitter release, and pigment granule distribution in the retinal pigment
epithelium (RPE), have been suggested to be affected by a defective MYO7A protein (Hasson,
1999; Hasson et al., 1997b; Liu et al., 1998a; Liu et al., 1999a; Richardson et al., 1997; Self et al.,
1998).
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REVIEW OF THE LITERATURE
1. The Finnish disease heritage
The Finnish disease heritage is a well-known concept, and was first time published by Norio,
Nevanlinna and Perheentupa in 1973. There is evidence of habitation already some 10,000 years
ago in Finland, although the present-day population is thought to have expanded from a small
number of founder settlers of Baltic Finnic and Germanic origin, who immigrated from the south
over the Gulf of Finland some 2,000-2,500 years ago, and populated all the coastal areas of the
southern and the western parts of Finland, also called the early settlement region (Nevanlinna,
1972; Norio, 1973). In the 12th century, the number of inhabitants was approximately 50,000,
and as late as the 15 th century, the number of total population reached 250,000 (de la Chapelle,
1993; de la Chapelle and Wright, 1998; Nevanlinna, 1972; Peltonen et al., 1999). Although
genetic bottlenecks (a remarkable decrease in the size of population followed by growth of the
original population), such as famine, war, and diseases, prevented the rapid growth of the
population, by the end of the 16th century the population had spread over from the coastlines and
the area of South Savo, towards the east, to the central, western and northern parts of Finland.
During a century, the new Finland, or late settlement region, was finally settled (de la Chapelle,
1993; de la Chapelle and Wright, 1998). Thereafter, the Finnish population has expanded fast to
its present number of 5,100,000.
As a consequence of the special Finnish population history characterized by national and
regional isolates with rapid expansion and random sampling of inhabitants from the original
population, some disease alleles became enriched and formed the Finnish disease heritage, while
certain disease alleles, such as cystic fibrosis and phenylketouria, disappeared almost completely
(de la Chapelle, 1993; de la Chapelle and Wright, 1998; Norio et al., 1973; Peltonen et al., 1999).
Compared to other populations, most of these diseases in Finland are associated with high gene
frequencies and low mutation rate, and they exhibit excessive locus homogeneity (Peltonen et al.,
2000). Most diseases show regional clustering, but some of the mutations are enriched all over
the country, and were probably carried with an early immigrant to Finland (de la Chapelle, 1993;
de la Chapelle and Wright, 1998, Peltonen et al., 1999). However, sometimes multiple  mutations
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account for the disease of regional subisolates, as is exemplified in X-linked recessive
choroideremia, CHM (Sankila et al., 1991; Sankila et al., 1992), and X-linked juvenile
retinoschisis, RS (Huopaniemi et al., 1999).
The past success in identifying the disease genes in Finland via the random mapping and
further fine mapping by haplotype-based restriction analysis has been assisted by features that
population isolate possesses, such as population founding sufficient time ago, large population
size, and absence of significant immigration during rapid expansion (de la Chapelle and Wright,
1998). Therefore, the subisolates have more uniform genetic and environmental background,
prevalence of certain diseases is high, and the diagnostic and phenotypic criteria are easily
standardized based on the high quality of good medical and epidemiological registers (Peltonen et
al., 2000). Genealogical records include the accurate church records, which allows tracing of the
families and ancestors back to the 16th century.
To date, the Finnish disease heritage comprises some 35 genetic disorders more prevalent
in Finland than in other populations, and at least 24 disease genes have been identified, which
offer a profound basis for functional studies and understanding of the disease mechanisms (de la
Chapelle and Wright, 1998; Kere, 2001; Peltonen et al., 1999; Peltonen et al., 2000; Ridanpää et
al., 2001). The list includes its own unique set of autosomal recessive diseases, however, two
autosomal dominant (amyloidosis type V; FAF, and tibial muscular dystrophy; TMD) and two X-
chromosomal (CHM and RS) patterns of inheritance are also included (de la Chapelle and
Wright, 1998).
2. Identification of genes
2.1. The Human Genome Project (HGP)
Detailed information of the human genome sequence offers advances to increase our
understanding of genetics and the nature of genes in health and disease. The effort for complete
sequencing of human genome was first formally proposed in 1985-1986, and officially it led to
the initiation of the Human Genome Project (HGP) in 1990. Many different sequencing centers
and hundreds of scientists around the world shared the forthcoming work. The strategy "map first,
sequence later", and the principle that all sequencing data were publicly and freely accessible was
adopted in the project (Collins et al., 1998). Sequencing the genomes of several other organisms
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was also included in the project, many of which have already been completely sequenced, such as
the yeast Saccharomyces Cerevisae (Goffeau et al., 1996), the nematode Caenorhabditis elegans
(The C. elegans Sequencing Consortium, 1998), the fruitfly Drosophila melanogaster (Myers et
al., 2000), and the plant Arabidopsis thaliana (Arabidopsis Genomics Initiative (AGI), 2000)
genomes.
At the 5-year point, the first major task of the HGP was to generate detailed high-
resolution genetic and physical maps of the entire human genome (Lander et al., 2001). The work
progressed fast, and in 1994, the HGP had constructed high-resolution maps, which were used for
sequencing and assembling the overall draft genome sequence. By the end of 1998, large-insert
clone contigs had been assembled, and approximately 180 megabases (Mb) of the human genome
had been completed. During the following years, 1999 and 2000, the first complete human
chromosome sequences for chromosomes 22 and 21, respectively, were published (Dunham et
al., 1999; Hattori et al., 2000). Finally, in February 2001, the first complete draft consisting of
about one billion bases of the human genome was published (Lander et al., 2001). At the same
time, a private company, Celera Genomics, published another draft sequence incorporating all of
the public project's accessible data with the whole genome shotgun data of their own (Venter et
al., 2001).
2.1.1.The first draft of the human genome
The estimated total size of the human genome is 3.2 gigabases (Gb), of which 2.95 Gb is
euchromatic (Baltimore et al., 2001). More than 90% of this region is represented in the
sequenced clones of the HGP and Celera, and over 94% can be found in the combined publicly
available sequence databases (Lander et al., 2001). More than 1.4 million single nucleotide
polymorphisms (SNPs), meaning one SNP per 1.91 kb of genomic sequence, have also been
identified (Sachidanandam et al., 2001).
Even with the availability of the first human genome draft sequence, gene identification in
the genomic sequence presents with challenges. The most suprising finding of the HGP was that
although the human genome is around 30 times larger than the worm and fly genomes, there
appear to be only some 30,000-40,000 genes coding for proteins which is only twice as many as
in worm or fly (Lander et al., 2001; Venter et al., 2001). It may turn out that these numbers are
underestimations, since some genes are expressed in rare tissues or encode small proteins, and
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may have been missed in these predictions. On the other hand, some predictions may correspond
to pseudogenes or gene fragments, giving a spurious estimate. Other recent estimates of gene
number vary from 35,000 to 120,000 genes (Ewing and Green, 2000; Liang et al., 2000; Wright
et al., 2001). These numbers are not directly comparable, since the sequence annotations are
based on different prediction programs and techniques.
Assuming that the human genome consists of approximately 30,000 genes with an
average gene size of about 30 kb and transcript size of 1.4 kb, then only 1.5% of the genome
codes for proteins, and various types of repeat sequences form over half of the genome (Lander et
al., 2001). The rest of the sequence contains regulatory regions, such as promoters and
transcriptional sequences, as well as unknown features (Baltimore, 2001; Birney et al., 2001;
Lander et al., 2001; Venter et al., 2001). Genes seem to be more complex than has been thought.
The different combinations of exons produced by alternative splicing, which affects more the
coding sequence than the 5'- or 3'-untranslated regions (UTRs), are seen for approximately 60%
of the genes, and are thought to yield a large number of protein products. Proteins appear to be
complicated, and the diversity of the human proteome is emphasized by innovation in the creation
of new proteins and their post-translatorial modifications (Lander et al., 2001). After evaluating
all the proteins potentially encoded in the genome, the public consortium concluded that although
humans do not have more types of protein domains than lower organisms, they use those domains
in a new manner, assembling new proteins from old parts. The second phase draft of the human
genome, to fill the remaining gaps and provide a more accurate catalogue of genes, is now under
way and will hopefully be completed by 2003.
2.2. Identification and isolation of genes by positional cloning methods
Positional cloning is a process whereby genes responsible for a disease are identified as a direct
result of genetic analysis, without any prior knowledge of the defective gene product, in a multi-
step process. First, the gene is localized to a particular region of a chromosome by linkage
analysis, utilizing families, in which the disease locus segregates. This preliminary localization is
followed by a detailed molecular analysis of the region, including genetic fine mapping: the
region of interest is covered in a series of overlapping genomic clones (YACs, BACs, and
cosmids), DNA isolation, transcript identification, cDNA cloning, and mutation searching of
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candidate genes. The proof for identifying a disease gene is that it carries the mutations that
segregate consistently with the disease in the families.
Positional cloning of disease genes has progressed rapidly because of the information
provided by the HGP. Although many disease genes have been identified successfully by this
method, for example the cystic fibrosis gene, CFTR (Rommens et al., 1989), and the diastrophic
dysplasia gene, DTD (Hästbacka et al., 1994), generally this strategy can be very laborious. The
size of the critical region defined by linkage analysis usually remains several megabases
containing dozens of genes. Instead, positional cloning using approaches, such as linkage
disequilibrium and/or large-scale sequencing of genomic clones, followed by transcript mapping,
assists genetic mapping to be taken to a very high resolution, and finally the identification of a
disease gene.
The positional candidate gene approach is based on strategies to identify candidate genes
by a combination of map position, expression, function, or homology to a relevant gene in a
model organism. An obvious positional candidate gene was suggested based on the linkage
analysis of an Irish retinitis pigmentosa family mapping the disease gene to chromosome 3q, on
the same region next to the human rhodopsin (RHO) gene (McWilliam et al., 1989). Later, a
novel RP1 mutation was identified in the RHO gene (Farrar et al., 1992). Recently, a functional
candidate gene approach was used successfully in mapping of the megaloblastic anemia 1
(MGA1) locus to the same region with the candidate gene encoding the intrinsic factor (IF)-B12
receptor cubilin, CUBN, and in the identification of the underlying mutations in the Finnish
MGA1 families (Aminoff et al., 1999).
The position independent candidate gene approach, which is based solely on the
molecular pathology of the disease or the phenotypically related diseases, is rarely very
successful. Instead, when biochemical basis of a disease is known exactly, it is possible to
characterize the gene product through functional cloning approach. The normal protein sequence
is determined by aminoacid sequencing or by purifying the corresponding mRNA by
immunoprecipitation using antibodies raised against the gene product, followed by probing
cDNA libraries with either a combination of gene-specific oligonucleotides or orthologous
cDNA, respectively. This approach was used successfully in the characterization of the
corresponding mutated genes encoding the blood clotting factor VIII in hemophilia A patients
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(Gitschier et al., 1984), and the enzyme phenylalanine hydroxylase (PAH) causing
phenylketonuria (Robson et al., 1982).
2.2.1. Linkage and linkage disequilibrium analyses
The common method to search for disease genes is to use linkage analysis to reveal the initial
disease locus, followed by haplotype analysis to refine the genetic region of interest (Peltonen et
al., 2000). The basic idea for linkage analysis is to trace and measure the cosegregation of disease
in a given family with marker loci. If the marker locus and the disease gene are linked, the allele
at that marker locus is likely to travel with the disease, and the distance between these loci can be
calculated by using information from putative recombination events during meiosis (Ott, 1991;
Terwilliger and Ott, 1994). The proportion of recombination, recombination fraction (θ), is the
likelihood of recombination between the loci. The genetic distance is generally measured in
centiMorgans (cM), where 1 cM is approximately the distance between two loci that on average
show 1% of recombination (θ = 0.01). The extent of linkage is measured by formulating a LOD
(logarithm of odds) score (Z), which is the logarithm of the likelihood ratio comparing the
hypothesis of linkage between two loci at certain recombination fraction with the hypothesis of
random recombination (θ = 0.5). The maximum value of the LOD score (Zmax) gives a measure of
the statistical significance of the result; a LOD score of 3 (odds ratio 1000:1) or more implies a
significant linkage. The closer the marker is to the disease gene, the greater the extent of
cosegregation and the higher the LOD score. The recombination fraction at Zmax is the most likely
estimate of the genetic distance between the loci. Negative LOD scores of less than -2 exclude
linkage for a marker and can be used as a measure for exclusion mapping.
Due to limited number of families and generations in analysis, linkage can be detected
over large genetic distances. Most often, these regions remain megabases in size, and are
therefore too large for effective cloning of the gene (de la Chapelle and Wright, 1998). Linkage
disequilibrium (LD) analysis usually overcomes this problem and can be used as a method to
complete fine-scale gene localization (de la Chapelle, 1993).
In linkage disequilibrium analysis, information from meiotic events throughout dozens or
hundreds of generations are evaluated by assuming that the disease-causing mutation occurred in
a n i n d i v i d u a l as a f ou n d e r ef f e c t , an d t h e exp a n s i on of th e po pu l a t i on ha s oc c u r r e d by   g r o w t h 
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rather than by immigration (de la Chapelle and Wright, 1998). Moreover, enough time has
elapsed since the founding, and the population size of the affected individuals is large enough in
the analysis. Generally, LD is referred to as a measure of the degree of non-random association of
two markers. If LD exists, the alleles at nearby markers are in association with the disease at the
population level. Errors in the calculations of the relationship between LD and marker locus
physical distances probably will happened, for example, if the disease gene frequencies in the
studied population are estimated wrong or multiple founding mutations exist instead of one (de la
Chapelle, 1993; Jorde, 2000).
Linkage disequilibrium analysis utilizes several statistical formulas in calculating allelic
association, and the use of multiple markers can enhance the power and accuracy of LD mapping.
The strength of the allelic association can be calculated by the use of a nonparametric statistical
test, such as a likelihood based program DISMULT, which analyses association for multiple loci
simultaneously (Terwilliger, 1995). An assumption of a small number of founders followed by
rapid expansion of population in a given isolate led Hästbacka et al. in 1992 to adapt a modified
formula, which was originally developed for the study of mutation rates in bacterial cultures
(Luria and Delbrück, 1943). This method was used successfully in the localization of the
diastrophic dysplasia (DTD) gene.
Search for common ancestral haplotype shared by the affected individuals is often done as
a part of linkage or LD analysis, and offers an excellent shortcut for disease mapping (Peltonen et
al., 2000). In haplotype-based recombination analysis, the common ancestral haplotype is
disrupted by multiple historical recombinations, and the conserved region suggests the position of
the gene precisely. The size of the chromosomal region showing LD depends directly on the
number of generations from the founder (Peltonen et al., 1999). The more extended the conserved
region is, the more recently has the mutation occurred in the population. In congenital chloride
diarrhea, CLD, the ancestral haplotype was conserved throughout a 12-cM genetic interval,
suggesting that a single founder mutation has been subjected in the population only some 15-25
generations ago (Höglund et al., 1995). In contrast, in progressive myoclonus epilepsy (EPM1)
(Lehesjoki et al., 1993), the ancestral haplotype consisted of a 5-cM interval, referring to a
founder mutation having occurred some 100 generations ago. Fine mapping of the chromosomal
regions by linkage disequilibrium has been extremely helpful in refining the localizations of the
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above-mentioned as well as many other Finnish diseases, and led to the isolation of their
respective genes (de la Chapelle and Wright, 1998; Peltonen et al., 1999).
2.2.1.1. Polymorphic markers
Recent advances in high-throughput sequencing and genotyping technologies have enabled
geneticists to easily characterize genetic variation at the nucleotide level. In the 1980s, the first
generation polymorphic DNA markers were based on restriction fragment length polymorphisms
(RFLPs). RFLPs have only two alleles depending on the presence or absence of a specific
enzyme restriction site (Botstein et al., 1980). Since their scoring by digestion of DNA followed
by Southern blotting and hybridization was laborious and time consuming, the invention of
polymerase chain reaction (PCR) technology enabled a more specific and fast amplification of the
region of interest. To date, the use of multiallelic and thereby very informative variable number
of tandem repeats (VNTRs) is preferred in genotyping.
During the 1990s, RFLPs were mostly replaced by simple tandem repeats (STR),
consisting of di-, tri- or tetranucleotides, in the study of monogenic diseases (Livak et al., 1995).
STRs are preferred in semi-automated systems of genotyping, as they are evenly and widely
distributed across the human genome, and display high levels of allelic variation (Gray et al.,
2000). However, recent interest of analyzing complex multifactorial diseases has raised the
favour of using single base polymorphisms (SNPs). Dense maps of SNP markers and the
discovery of intragenic SNPs have provided excellent tools to be used in linkage and association
studies (Kwok, 2001). Of the 1.42 million SNPs identified by the International SNP Map working
group, 60,000 were found to be within genes, and the amount of diversity varies within the
genome (Sachidanandam et al., 2001). Generally, transitional base changes are more common
than transversions, and CpG dinucleotides display the highest mutation rate (Gray et al., 2000).
Although SNPs are less informative, they are more stable than STRs due to lower mutation rates.
To date, the NCBI dbSNP database (http://www.ncbi.nlm.nih.gov/SNP/index.html) contains
already over 2.5 million reference SNP entries.
2.2.2. Physical mapping
The primary goal of physical mapping is to identify and isolate a gene in the genomic clones that
have been mapped to a certain chromosomal region defined by recombinants or allelic association
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in genetic mapping. The initial physical mapping and DNA isolation of large genomic clones has
been greatly advanced by the ability to clone large fragments of DNA in yeast artificial
chromosomes (YACs) (Burke et al., 1992). YAC libraries can be screened for selected
chromosomally positioned DNA markers, termed sequence tagged sites (STSs), in order to
construct regional maps, and to join individual overlapping fragments into contiguous fragment
arrays. Overlapping YAC clones covering up to several megabases can then be characterized
individually and reassembled into the genome. However, in isolation of new polymorphisms and
expressed sequences, YAC clones may be too large or chimeric, and are therefore complemented
by contigs of overlapping P1-artificial chromosomes (PACs) or bacterial artificial chromosomes
(BACs). These clones are selected for shotgun sequencing, and the genomic sequence is
reconstructed by assembly of overlapping clone sequences. Recently, as a part of the HGP
sequencing project, the International Human Genome Mapping Consortium reported a large
human whole-genome BAC map combined with previous genetic maps (McPherson et al., 2001).
They also inserted the new data into the database, which can be found from
http://genome.wustl.edu/gsc/human/mapping/index.shtlm. Similar physical maps based on BAC
clones have been used in sequencing other large genomes, and the technique is being applied to
the mouse genome as well (Bouck et al., 2000).
2.2.3. Identification of genes from cloned DNA
Several traditional approaches are available for gene identification from cloned DNA. These
include searching for evolutionary conservation of DNA fragments by hybridization to Southern
blots of genomic DNA isolated from multiple species (zoo blots) (Claudio et al., 1994),
identification of CpG islands as signposts for the 5' end of genes (Larsen et al., 1992), cDNA
selection (Lovett et al., 1991; Parimoo et al., 1991), and exon trapping (Duyk et al., 1990).
Similarly, conserved DNA fragments can be tested for expression by hybridization to multiple-
tissue northern blots of RNA isolated from fetal and adult human tissues (Alwine et al., 1977). If
a transcript is identified, the genomic DNA fragment can be subsequently hybridized to specific
tissue cDNA libraries (Bonaldo et al., 1994).
The dinucleotide CpG islands are of particular interest because many are associated with
5' ends of genes, and they can be identified by cleavage with restriction enzymes (Larsen et al.,
1992), and more recently, by genomic annotation software (see below). The density of CpG
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islands varies, and correlates reasonably well with estimates of relative gene density on different
chromosomes.
In cDNA selection strategy, an amplified cDNA library is hybridized for example to YAC
inserts or cosmid clone sequences (Lovett et al., 1991; Parimoo et al., 1991). Hybridized cDNA
inserts are then eluted and amplified by PCR. The process is repeated two or three times before
cloning the selected cDNAs. The resulting cDNA sub-libraries are enriched for expressed
sequences from the genomic region, but still require thorough characterization because of
simultaneous selection of cDNAs with homology to pseudogenes and low copy number repeat
sequences in the genomic DNA template.
Exon trapping relies on functional sequences required for RNA splicing (Duyk et al.,
1990). Subcloned genomic DNA fragments are transfected into an appropriate eukaryotic cell line
and transcribed into RNA. If the genomic fragment contains an exon, it can be spliced properly
into mature mRNA after expression in mammalian cells in culture. This method relies on there
being only one splice site to be selected, and has the disadvantage of selecting genomic fragments
with cryptic splice acceptor sites, thereby trapping false positive exons.
In the past few years, new genes have been identified in many species by randomly
sequencing cDNA clones representing RNAs expressed in different tissues to produce expressed
sequence tags (ESTs), which have been collected into a single database dbEST (Adams et al.,
1991; Boguski et al., 1993). This kind of information obtained from a gene sequence and
expression, in combination with its possible chromosomal location, will implicate a candidate
gene for a disease that has been mapped to the same region (Ballabio, 1993).
As an alternative to hybridization to cDNA libraries on filters, EST fragments can be used
to design primers to obtain complete cDNA sequences using a method such as rapid amplification
of cDNA ends (RACE) (Frohman et al., 1988). On a larger scale, long stretches of genomic DNA
can be assembled by shotgun sequencing method, and potential exons identified using computer
algorithms. As automated sequencing and computer programs become more sensitive and
efficient at finding coding sequences, the approach of direct sequencing to find genes should
become more popular.
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2.3. Genome annotation through database searches
In around 1996, database searches or "research in silico" became a valuable tool in genomic
research because of accumulating sequences of partial gene sequences derived from mRNA of
human and other species (Boguski, 1995). To date, the attention is focused more on genomic
sequence annotation, for which new computational strategies for data generation are developing
rapidly. A "virtual mRNA" that reflects a probable transcript is based on the evidence of various
gene structures by different gene-prediction programs. However, detection of genes in silico
requires advanced bioinformatics technology and large-scale annotation of the genomic sequence.
The first step to characterize a gene is to construct a complete gene model by detection
and assembly of individual exons with 5' and 3' extremities of the putative transcript (Claverie,
1997). Computational methods can be divided into homology-based methods and those based on
general properties of protein-encoding genes. Homology-based gene prediction software detects
sequences that are associated with already known genes, ESTs, and complementary DNAs. In
general, it gives more reliable evidence of a putative gene than prediction without knowledge
about other similar genes (Birney et al., 2001). The general properties of genes include promoter
regions, splice sites, open reading frames, initiation and termination codons, and 3' untranslated
regions.
Gene finding should be based on combinations of different prediction programs, and it
depends on the quality and quantity of sequence data in use. Despite the vast progress in
developing accurate annotation programs, some prediction programs tend to overlook gene
numbers by producing false positives. Sequencing errors and contigs with gaps cause disrupted
reading frames (Birney et al., 2001). The genes themselves can be separated by long stretches of
noncoding DNA, and the total sizes of introns occasionally extend thousands of bases between
exons, as is exemplified in the human dystrophin (DMD) gene spanning over 2.5 Mb of the X-
chromosome (Pozzoli et al., 2002). Although, the overall sizes of exons are more constant
compared to introns, some genes have a considerable number of exons. For example, the human
titin (TTN) gene comprises 178 exons of over 80-kb coding sequence (Labeit and Kolmerer,
1995). Alternative splicing of exons, which most of the programs do not recognize, further
complicates construction of genes. Rarely active or highly tissue specific genes are not always
detected in searches of expressed genes (Birney, 2001; Lander et al., 2001). Moreover,
approximately 5% of the human genome contains large duplicated genomic segments of size of
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over 10 kb within the same chromosome or among different chromosomes resulting in copies of
genes or nonfunctional pseudogenes (Lander et al., Venter et al., 2001). All these features of the
genome undoubtedly complicate gene identification.
In the past, genomic sequences have been analyzed mostly by hand (Harris, 1997).
However, the rapid establishment of databases and the rate of sequencing have raised the need for
reliable automated techniques for interpreting long genomic sequences and for multiple
comparisons among the analyses. The most effective are the integrated gene prediction methods,
which provide accurate and automated predictions. Automated sequence annotation software
programs, such as Genotator (Harris, 1997) and NIX/PIX (Nucleotide/Protein Identify X, UK
HGMP Resource Center), notably enhance sequence analysis by combining and running series of
different gene-finding programs and homology searches simultaneously. Moreover, when several
different programs make the same prediction on a given sequence, the confidence in the
prediction is increased.
2.3.1. Similarity searches
Gene prediction makes use of different sequence similarity searches. Basic local alignment tools,
BLAST programs, perform similarity searches against EST, protein, and genome-sequence
databases (Altschul et al., 1990, 1997). Other programs, such as Repeat Masker2, screen
anonymous genomic sequences against repeat databases to filter so-called "junk" DNA prior to
similarity searches (Gish and States, 1993). Usually, similarity search programs do not detect an
entire gene, and combinations of other prediction methods are needed. Gapped BLAST allows for
insertions and deletions within the analyzed genomic sequence, whereas a new version of
BLAST, a position-specific-iterated BLAST (PSI-BLAST), detects similarities by a series of
repeated homology searches (Altschul et al., 1997). EST_GENOME (Mott, 1998) analyzes either
ESTs or cDNAs against genomic sequences based on a simple model of recognition of splice site
dinucleotides. As the human genome project is in a phase of systematic sequencing, different
intermediate forms of sequences are available within single-pass sequence of Genome Survey
Sequence (GSS) and High Throughput Genomic (HTGS) databases of GenBank.
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2.3.2. Predicting exons and gene-specific elements
To predict protein-coding exons and genes, several distinct types of programs have been
developed, for example Genscan (Burge and Karlin 1997), Grail (Uberbacher and Mural, 1991),
Genie (Reese et al., 1997), Fgene (Solovyev and Salamov, 1997), and MZEF (Zhang, 1997).
Most often, they search for conserved exon-intron structures, such as acceptor and donor splice
sites or specific signals for 5' exons (a TATA-box and/or a translation start site) and 3' exons (a
stop codon and/or a polyadenylation signal) (Claverie, 1997). There are certain limitations for all
of these programs. Most of them assume that the analyzed genomic sequence contains exactly
one complete gene structure. Therefore, most of the predicted genes contain incorrect exon
boundaries or exons are missed. Genscan is designed to predict partial genes, multiple genes and
single-exon genes in given genomic DNA, and it analyzes the genes occurring on either or both
DNA strands simultaneously (Burge and Karlin, 1997, Claverie, 1997). On the other hand, the
accuracy of all these programs is reduced significantly when analyzing large genomic contigs of
hundreds of kilobases.
To predict full extent noncoding parts of transcripts, determination of noncoding exons,
putative functional regulatory elements, promoter-containing regions, and 3' extremities is
needed. Unfortunately, most traditional gene prediction programs refer only to protein-coding
regions, and thereby do not recognize, for example, the noncoding first exons. Gene promoters
are located upstream from the translation start codon, and are frequently associated with CpG
islands of various sizes, frequency, and GC-content. The sequence signals that support
transcription units are TATA-boxes within the promoter region and polyadenylation signals
(AATAAA) downstream from the termination codon ending the transcription (Claverie, 1997).
Although many useful programs, for example, MatInspector/TRANSFAC (Heinemeyer et al.,
1999) and Neural Network Promoter Input (Knudsen, 1999), have been generated to identify
these potential consensus target sequences on genes, however, many genes do not have such
elements. Only 70%-80% of promoters contain a TATA box and a polyadenylation signal is
missing from over half of the 3' ends of transcripts (Claverie, 1997). Also, the functional non-
protein coding RNA genes are difficult to detect with the current prediction programs, since these
genes are untranslated, often small, and non-polyadenylated (Lander et al., 2001). They can
mainly be located by similarity searches corresponding to known RNA genes.
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2.3.3. Protein structure prediction
Many proteins in sequence databases have conserved sequence patterns based on which they are
categorized. Therefore, if two proteins share significant sequence similarity, they should also
have similar structures, and the search with a candidate sequence may discover a family or a
superfamily relationship with a known protein. The prediction and comparing the protein
structures to analyze the secondary structure, the functional domains, usually provides valuable
information, although increased confidence is reached when several methods give a similar
prediction (Mount, 2001).
Pattern-Hit Initiated BLAST, PHI-BLAST, (Zhang et al., 1998) combines the input
protein pattern search with the local similarity searches. For detailed analysis of proteins'
structural motifs, a number of programs are available in databases. SWISS-PROT (Bairoch and
Apweiler 1999), the Brookhaven Protein Databank, PDB, PROSITE (Hofmann et al., 1999), and
Pfam (Bateman et al., 1999) databases are among the most extensively used databases for protein
function, domain structure, motifs, families, and post-translational modification. PSORT (Nakai
and Horton, 1999) predicts the presence of protein localization signals, whereas SignaIP predicts
the location of signal peptide cleavage sites in proteins (Nielson et al., 1997). A hydrophobic α-
helix, typically 20-30 residues in length, is a good indicator that the region spans a membrane,
and can be predicted with the program Tmpred (Kyte and Doolittle, 1982; Hofmann and Stoffel,
1993).
2.3.4. Comparative genomics and model organisms
Large genome sequencing projects of different organisms have made possible to predict the
function of similar genes in different organisms. Therefore, sequence comparison of genomes of
various species is an excellent technique to discover genes and other important regions.
Especially, comparisons between human and mice sequences have become a particularly
effective resource for studies of human genes, since mouse and human genes often fall into
homologous chromosomal regions that have a conserved gene content (Marra et al., 1999).
Moreover, identifying of disease genes in mice is a more practicable method, since multiple
backgrosses yield a high density of recombination breakpoints within the genetic interval of
interest. To find a putative orthologue (i.e. related gene in other species), the most useful way is
to compare protein products between species. By comparing human sequences with sequences
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from other species, it has been shown that 40% to 60% of the predicted proteins give some
sequence similarity to other species, for example fruitfly and worm (Rubin, 2001). Databases,
such as XREFdp (Bassett et al., 1995), can be used to compare and align genomic sequences of
different model organisms.
Table 1. Selected programs for performing gene and protein predictions
NAME SOURCE REFERENCE
BLAST, PHI-BLAST, PSI-
BLAST
http://www.ncbi.nlm.nih.gov/
BLAST
Altschul et al., 1990,
1997; Zhang et al., 1998
EST_GENOME http://www.hgmp.mrc.ac.uk/
Registered/Option/est_genome.
htlm
Mott 1998
GSS, HTGS http://www.ncbi.nlm.nih.gov/ See web
FGENE http://genomic.sanger.ac.uk/gf/
gf.shtlm
Solovyev and Salamov,
1997
GENSCAN http://genes.mit.edu/GENSCAN.
htlm
Burge and Karlin, 1997
GENIE http://www.cse.ucsc.edu/∼dkulp/
cgi-bin/genie
Reese et al., 1997
GRAIL http://compbio.ornl.gov/ Überbacher and Mural,
1991
MZEF http://argon.cshl.org/genefinder/ Zhang, 1997
NIX and PIX http://www.hgmp.mrc.ac.uk See web
PDB http://www.rcsn.org See web
Pfam http://www.sanger.ac.uk/Pfam Bateman et al., 1999
PROSITE http://www.expasy.ch/prosite Hofmann et al., 1999
PSORT http://psort.nibb.ac.jp/ Nakai and Horton, 1999
SWISS-PROT http://www.expasy.ch/sprot/ Bairoch and Apweiler,
1999
MatInspector/TRANSFAC http://www.gsf.de/cgibin/
matsearch.pl
Heinemeyer et al., 1999
Neural Network Promoter
II Input
Repeat Masker2
http://www.cbs.dtu.dk/services/
promoter
http://www.genome.washington.edu/
UWGC/
Knudsen, 1999
See web
SignalP http://www.cbs.dtu.dk/services/
SignalP/
Nielsen et al., 1997
Tmpred http://www.ch.embnet.org/
software/TMPRED_form.html
Hofmann and Stoffel,
1993
XREFdp http://www.ncbi.nlm.nih.gov/
XREFdb/
Bassett et al., 1995
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2.4. Mutation identification
Many of the current techniques for mutation identification rely on the finding of conformational
changes in either double or single-stranded DNA fragment which are distinguished by
electrophoresis based on their differential migration in an electrical field. Since single-base
changes are the most common type of mutations in the human genome, most of the techniques
detect sequence mismatches in heteroduplexes between allelic DNA fragments or single-stranded
DNA which adopt slightly different conformations under nondenaturing conditions (Kwok,
2001). All the mutation identification methods have their limitations and none of them are 100%
sensitive. Depending on the technique used, they detect mutations on small, 100-600 bp,
fragments. Mostly, they do not reveal the site or the type of the mutation, and the sequence
context of a base change has an effect on mutation identification. Moreover, mutations are
difficult to detect if they are in the domain of high melting-temperature. Methods, such as single
strand conformation polymorphisms analysis (SSCP) (Orita et al., 1989), heteroduplex analysis
(HA) (Lichten and Fox, 1983), denaturing gradient gel electrophoresis (DGGE) (Fischer and
Lerman, 1979), direct DNA sequencing, and variant detector arrays (VDAs) (Wang et al., 1998)
are most commonly used for mutation identification.
In SSCP analysis, the amplified DNA fragments are electrophoresed in a nondenaturing
polyacrylamide gel, where they form the secondary structures according to their sequence contex.
Mutated fragments are identified as a result of their divergent migration pattern. This method
detects typically 70% to 95% of the mutations.
In heteroduplex analysis, the denatured DNA fragments reanneal and form a
heteroduplex, which can be detected as a band shift on a gel. To enhance formation of
heteroduplex structures, wild type and mutant samples are crossmatched by mixing and letting
them reanneal after denaturation. Lately, the most popular detection system for heteroduplexes
due to simplicity, low cost, and high rate is to run the samples on a high-performance liquid
chromatography (HPLC) column (Gray et al., 2000). The subsequent mutation detection is based
on differential retention of the heteroduplexes in the column.
Denaturing gradient gel electrophoresis (DGGE) allows the identification of point
mutations, which alter the melting behavior of the DNA fragment analyzed. The analysis is based
on the electrophoretic mobility of a double-stranded DNA molecule, as mismatches reduce the
mobility of heteroduplexes compared with homoduplexes, through linearly increasing
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concentration of denaturing agents, such as formamide and urea. The introduction of a GC-rich
domain (GC-clamp) to the DGGE PCR primers increases the mutation detection close to 100%
(Myers et al., 1985).
While sequencing techniques, and sample capacity per run in capillary systems, have
developed enormously during the past years, direct sequencing is usually the favored choice for
mutation detection. When scanning large amounts of samples and especially single nucleotide
polymorphisms, a comparable method for sequencing is the recently adapted VDA technology.
Mutations are detected by hybridization of a PCR product to a glass chip containing
oligonucleotide arrays. The difference in hybridization strength between matched and
mismatched nucleotides detects the mutation (Gray et al., 2000).
2.5. Analysis of gene expression
To understand gene function, it is important to know about gene expression. Many technologies
are now available for the analysis of patterns of gene expression. Northern blot hybridization and
reverse transcriptase polymerase chain reaction (RT-PCR) allow the detection of rough resolution
expression patterns of RNA from different tissues or cell lines. Cell specific localizations of RNA
within tissues are normally obtained by in situ hybridization (Wilkinson and Green, 1990). For
computational methods, gene indexes, such as UniGene and SAGE (serial analysis of gene
expression) (Velculescu et al., 1995), provide information about the tissues, in which different
transcripts are expressed. However, in recent years the "chips" or microarray techniques are being
used to bring together expression data at enormous capacity (Brown and Botstein, 1999). With
these methods it is possible to monitor the differences in expression of individual genes and RNA
samples from multiple tissues under different physiological conditions by using thousands of
target DNAs or entire genomes. The expression and function of genes can be characterized in
vitro using cultured cells, but the development of the technology to manipulate mammalian genes
in embryonic stem cells (ES) combined with the generation of transgenic mice, has made possible
to express genes in mice, and create germline gain-of-function and loss-of-function mutations
(Camper et al., 1995).
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3. The human retina and the phototransduction pathway
The human neural retina (Figure 1. A) comprises three layers of cells. The outer nuclear layer
contains two kinds of photoreceptor cells, of which 5% are cones and 95% rods. Cones, which
mediate colour vision, are concentrated within the central part of the retina, the fovea, which is
the area of highest visual acuity. The fovea is surrounded by the rods, which are responsible for
vision in dim light. The outer segment of the photoreceptor is filled with phototransduction
proteins-containing discs, which are shedded from the tip of the photoreceptor and constantly
renewed. Photoreceptors synapse in the outer plexiform layer with a second, inner nuclear layer
of bipolar cells, as well as with horizontal and amacrine cells, which process the visual
information. The third ganglion cell layer contains amacrine cells as well as ganglion cells, which
send their axons along the inner surface of the retina coming together at the optic disc to make up
the optic nerve (Rattner et al., 1999). Adjacent to the neural retina is the retinal pigment
epithelium (RPE), which functions on phagocytotic processes of the photoreceptor outer
segments and transport of metabolites.
Phototransduction is a G-protein (GTP-binding regulatory protein) -coupled enzymatic
cascade to amplify the signal derived from the light-absorbing visual pigment of rods, rhodopsin,
which consists of an apoprotein opsin (Rattner et al., 1999). Photoactivation requires a continuous
recovery of active rod opsin by regeneration of covalently bound chromophore 11-cis-retinal, a
vitamin A-derivative, through isomerization cycle in the RPE and in the photoreceptors. Figure 1.
(B-C) explains the phototransduction cascade in detail. A similar phototransduction cascade has
been also proposed for cone photoreceptors, but other photopigments are involved in the cascade.
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Figure 1. (A). Schematic drawing of the retina. The major cell types are shown: retinal pigment epithelium (RPE),
photoreceptor, bipolar cells, horizontal cells, amacrine cells, and ganglion cells. A photoreceptor is composed of an
outer segment (OS), a connecting cilium (CC), and an inner segment (IS). Adapted from web
http://thalamus.wustl.edu. (B). Schematic representation of phototransduction pathway. Light enters through the
ganglion cell layer, and must penetrate all the other cell layers before it reaches the rod and cone outer segments,
containing the visual pigments. Phototransduction begins with the photoactivation induced conformational changes
of rhodopsin (R*), which in turn activates the G-protein, transducin. Transducin, bound to GTP (T-GTP), triggers the
enzymatic activity of cGMP phosphodiesterase (PDE), which then hydrolyses cGMP to GMP. (C). The low level of
cGMP leads to closure of the cGMP-gated Na+- and Ca2+-channels at the plasma membrane and cell
hyperpolarization. Finally, the membrane hyperpolarization leads to the release of the neurotransmitter at the
photoreceptor synapse. Within the outer segment of the photoreceptor, drop of intracellular calcium levels activates
the guanylate cyclase, which leads to an increase of the cytosolic cGMP concentration and causes the re-opening of
the cGMP-gated cation-channels. Reassociation of transducin and phosphodiesterase subunits, as well as inactivation
of rhodopsin by phosphorylation and binding of phosphorylated arrestin, completes the visual cycle (Gregory-Evans
and Bhattacharaya, 1998).
* Activated.
ganglion cell layer
T-GDP
T-GTP*
R
R*
PDE PDE*
GMP
Na+, Ca2+
channels
closed
Na+, Ca2+
channels open
Intracellular
cGMP
cGMP
retinal pigment
epithelium (RPE)
OS
CC
IS
discs
inner nuclear layer
outer nuclear layer
inner plexiform layer
outer plexiform layer
light
A.
Membrane
hyperpolarization
Neurotransmitter
release
Intracellular
Ca2+
Guanylate
cyclase
B.
C.
32
3.1. Retinitis Pigmentosa (RP)
Inherited retinal diseases are a common cause of visual impairment in children and adults which
result in a severe loss of vision. Retinitis pigmentosa (RP) is the most frequent form of inherited
retinopathy with an incidence of 1 in 3,500 individuals worldwide (Sullivan et al., 1999). The
disorder is genetically heterogeneous with approximately 80% of the patients having autosomal
recessive forms of RP. Autosomal dominant and X-linked forms account each for approximately
10% of the patients. RP is characterized by night blindness, progressive constriction of the visual
field leading to tunnel vision, abnormalities present on electroretinography, and pigmented
fundus abnormalities (Roepman et al., 1996).
Advances in molecular genetics have provided new insights into the genes responsible for
the pathogenic mechanisms of RP. The genetics of RP is complex, and 79 genes causing retinal
disorders have been cloned to date, and additional 53 have been mapped, but not yet identified
(RetNet, http://www.sph.uth.tmc.edu/RetNet). RP is the result of mutations in a wide variety of
genes encoding proteins located in the photoreceptor cells and in the RPE, and components of
phototransduction cascade (Gregory-Evans and Bhattacharaya, 1998). RP affects the sensory
cells, the photoreceptors, which gradually deteriorate and die, the rods before the cones. To
understand the mechanisms of photoreceptor cell death, invertebrate and vertebrate models
carrying mutations in the genes implicated in human retinal diseases have been examined (Travis,
1998). For example, induction of apoptotic pathways leading to degeneration of retinal cells has
been suggested to be associated in RP based on the studies of Drosophila visual system mutants,
in which the mutations in the genes encoding visual cascade components, such as phopholipase
C, arrestin and phosphatidylinositol transfer protein, lead to abnormal accumulation of rhodopsin-
arrestin complexes in the photoreceptor cell (Alloway et al., 2000). In electron micrographs, the
retinas of these mutants appear abnormal with large intercellular holes and vesicular bodies
adjacent to photoreceptor cells. A possible mechanism for photoreceptor degeneration in RP,
caused by a mutation in the peripherin-RDS (retinal degeneration slow)-gene (Farrar et al., 1991),
is exemplified in rds/rds null mouse mutant, which fails to form outer segments of
photoreceptors. Loss of the outer segments and, thereby, loss of the cGMP-gated ion-channels
results in toxic levels of oxygen in photoreceptor cells leading to cell death (Travis, 1998).
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4. The human ear and the mechanisms of normal hearing
The adult mammalian ear is made up of three distinct parts, the external, the middle, and the inner
ear (Figure 2). Sound is collected by the external ear comprising the auricle and the external
auditory canal, and transmitted to the tympanic membrane in the middle ear. In the middle ear,
the three auditory bones, the malleus, the incus, and the stapes, transmit the sound waves to the
oval window of the inner ear. The inner ear regulates two sensory systems, the auditory system,
which is responsible for hearing, and the vestibular system, which sensors orientation and
balance. It consists of two labyrinths, a membranous labyrinth filled with the endolymph in a
cavity of bony labyrinth, which contains the vestibule, the cochlea, and the semicircular canals
with the sacculus and the utriculus immersed with the perilymph (Petit, 1996; Willems, 2000).
The membranous labyrinth consists of canals of the vestibular apparatus and the cochlear duct.
The cochlear duct contains the organ of Corti located between the tectorial and the basilar
membranes. In response to a movement of the basilar membrane and shearing of the tectorial
membrane induced by sound vibrations, the auditory receptors, the hair cell stereocilia, bend. As
a result, connecting tip-links between the stereocilia stretch followed by opening of the mechano-
gated potassium channels at the stereocilia membrane (Kalatzis and Petit, 1998).
Each hair cell consists of a kinocilium defining the orientation of a well-organized V-
shaped array of stereocilia in rows of graded height which has a vital role in hair cell mechano-
electrical transduction (Petit, 2001). Each stereocilium consists of an actin-core, which is
anchored into an actin cytoskeleton constituting the cuticular plate. The stereocilia are joined to
one another by the tip-links, which have been proposed to be the gating springs that regulate
opening and closing of the transduction channels located at or near the tip-links, through the
action of a motor protein, probably myosin (Gillespie and Corey, 1997; Petit, 1996). These motor
proteins move along actin filaments using energy from ATP hydrolysis. Due to the tension of the
stereocilia and tip links, a small portion of the channels are open, even in the rest (Steel and Kros,
2001). The mechanic stimulation of the stereocilia leads to an influx of endolymphatic potassium
resulting in hair cell depolarization. This leads to the release of neurotransmitter induced by the
inflow of calcium ions (Ca2+) on the basolateral side into the hair cell, thereby activating the
acoustic nerve (Hudspeth, 1997; Willems, 2000).
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Figure 2.  Drawing of the external (E), middle (M), and inner (I) ear. Adapted from web
http://www.iurc.montp.inserm.fr/cric/audition/.
4.1. Classification of hearing loss (HL)
Hearing loss (HL) is the most common sensory disorder in humans caused by genetic and
environmental factors, or both (Petit, 1996). Among the environmental factors, it can be caused
by meningitis, rubella, perinatal complications, bacterial and viral infections, trauma, and
ototoxic drugs, such as aminoglycosides. It is classified according to the age of onset as
prelingual or postlingual, and syndromic or nonsydromic hearing loss (Willems, 2000). Most
often, the hereditary hearing loss is caused by peripheral auditory defects, which can be
conductive (external or middle ear defects), sensorineural (cochlear defects) or mixed (Petit,
1996). Severity of hearing loss is measured in decibels (dB) of the loss of hearing level, and is
assorted as mild (27 to 40 dB), moderate (41 to 55 dB), moderate to severe (56 to 70 dB), severe
(71 to 90 dB), and profound (>90 dB) (Kalatzis and Petit, 1998).
Hereditary deafness can be monogenic and result from a mutation in a single gene or
multifactorial resulting from a combination of mutations in different genes and environmental
factors. In developed countries, approximately 60% of deafness have a genetic background, as
HL results from a mutation in a single gene (Marazita et al., 1993). Furthermore, approximately
70% of genetic HL is classified as nonsyndromic and the remaining 30% as syndromic hearing
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loss. Nonsyndromic HL can be divided according to mode of inheritance to autosomal recessive
(77%), autosomal dominant (22%), X-linked (1%) or mitochondrial (less than 1%), and the defect
is generally of sensorineural origin (Resendes et al., 2001).
The overall impact of HL is affected by the age of onset. HL at birth or during prelingual
period affects approximately 1/1000 infants. Postlingual HL results generally from a combination
of additional genetic and environmental causes and accounts for a further 1/1000 children before
adulthood (Morton, 1991; Resendes et al., 2001). Moreover, postlingual HL is more frequent than
prelingual HL, and affects normal communication in 10% of the population by the age of 65
years (Willems, 2000). Many of the recently identified deafness genes cause progressive HL that
begins in adulthood, suggesting that single genes may have an important role in HL in the
population as a whole (Steel, 1998).
4.2. Hereditary hearing loss is genetically and clinically heterogeneous
Knowledge of the molecular basis of normal auditory function, and the progress in identifying
genes involved in hearing loss has improved enormously over the past years. The molecular
composition of the different structures in the cochlea, and especially changes in structural
proteins have been associated with hearing loss. The mutated genes encode a large diversity of
molecules, including molecules of cytoskeletal components, extracellular matrix components,
transcription factors, enzymes, ion pumps, and mitochondrial genes (Kalatzis and Petit, 1998;
Steel and Kros, 2001).
At present, 26 new genes involved in non-syndromic and over 32 genes for syndromic
hearing impairments have been identified, some of the underlying genes being responsible for
both forms of HL (Hereditary Hearing Loss Homepage; Resendes et al., 2001). Phenotypic
variation from profound congenital to slowly progressing adult-onset HL results from allelic and
locus heterogeneity (Adato et al., 1999; Balciuniene et al., 1998; Keats and Berlin, 1999). HL
results from allelic heterogeneity, for example, in syndromic deafness USH1B (Weil et al., 1995),
in nonsyndromic DFNB2 (Liu et al., 1997d; Weil et al., 1997), and in DFNA11 (Liu et al.,
1997b), as well as in the atypical form of Usher syndrome (Liu et al., 1998b), where distinct
mutations in the myosin VIIA (MYO7A) gene have been shown to underlie these diseases.
Moreover, mutations in a gene encoding PDS, an anion transporter named pendrin, cause both
syndromic and nonsyndromic hearing losses in Pendred syndrome (Everett et al., 1997) and in
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DFNB4 (Li et al., 1998), respectively. Furthermore, correlation between different mutations and
phenotypes have been observed, for example in the case of cadherin 23 (CDH23), whose
mutations may lead to both syndromic (USH1D) and nonsyndromic (DFNB12) hearing loss
(Bolz et al., 2001; Bork et al., 2001). Digenic inheritance has been reported in a Swedish family,
whose affected members are carriers for mutations in two different genes, DFNA2 and DFNA12
(Balciuniene et al., 1998). Also, possible interaction between two different genes, USH1B and
USH3, giving the distinct phenotypes in an USH3 family of Jewish Yemenite origin, has been
suggested (Adato et al., 1999).
It is difficult to ascertain whether the mutation type accounts for the expression profile of
different phenotypes. Phenotypic variation between individuals with the same disease alleles can
be also due to genetic and/or environmental modulating factors, such as modifier genes at another
locus, which control the function and the expression of the gene underlying hearing loss
(Friedman et al., 2000). The possible role for a modifier gene has been suggested in maternally
inherited deafness associated with the A1555G mutation in the mitochondrial 12S ribosomal
RNA gene (Bykhovskaya et al., 2000). The aminoglycosides have been shown to trigger HL in
individuals with the A1555G mutation, though some patients with the A1555G mutation have a
congenital HL in the absence of exposure to aminoglycosides. Through a genomewide screen, a
nuclear locus for a possible modifier gene has been found for a mitochondrial DNA disorder
(Bykhovskaya et al., 2000). Although there are limited examples of modifier genes in humans,
they are expected to be a common cause of phenotypic variability, and are frequent in mice
(Nadeau, 2001).
5. Usher syndrome (USH)
Von Graefe (1858) and Liebreich (1861) documented the earliest descriptions of the simultaneous
occurrence of pigmentary retinopathy with deafness. Thereafter, Usher syndrome (USH), was
named after a Scottish ophthalmologist Charles Usher (1914), who was the first to emphasize the
recessive hereditary nature of the syndrome and suggested that it constituted a separate entity
among other forms of retinitis pigmentosa.
USH comprises a group of autosomal recessive disorders associated with bilateral
sensorineural deafness, loss of vision caused by retinitis pigmentosa, and variable vestibular
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deficit. It is the most frequent cause of genetically determined combined visual and hearing loss,
and accounts for more than 50% of the deaf-blind population (Boughman et al., 1983). Among
congenital deaf individuals and RP population, USH accounts for approximately 3%-6% and
12%-20%, respectively (Boughman and Fishman, 1983; Haim, 2002; Rosenfeld et al., 1994;
Vernon, 1969).
The prevalence of USH has been estimated at 2.4-3.6/100,000 in Scandinavia (Gröndahl,
1987; Hallgren, 1959; Lindenov, 1945; Nuutila, 1968; Nuutila, 1970) and at 4.4/100,000 in the
United States (Boughman et al., 1983). USH is enriched particularly in Northern Sweden and
eastern and northern parts of Finland, where the estimated prevalence is 10-21/100,000 (Hallgren,
1959; Nuutila, 1968; Nuutila, 1970). Recent studies suggest that Usher type 2 (USH2) is the most
common phenotype of the three subtypes of USH worldwide, accounting for more than half of all
the cases (Hope et al., 1997; Rosenberg et al., 1997), whereas USH1B seems to be the most
common variety of Usher type 1 (USH1) (Weston et al., 1996). In the United States and Northern
Europe, distribution of USH1 and USH2 patients varies between 33%-44% and 56%-67% (Petit,
2001), respectively. In Finland, there are more than 300 USH cases diagnosed, giving an overall
prevalence of 6.6/100,000. Of those, 40% have progressive hearing loss suggesting USH3,
whereas 12% account for USH2, 34% for USH1, and 14% for an unknown type (Pakarinen et al.,
1995a). In Birmingham, UK, in the population over 15 years of age, the prevalence for all USH
subtypes was 6.2/100,000 and USH3 was reported to account for 20% of all USH cases (Hope et
al., 1997).
5.1. Clinical classification of USH
The existence of genetic heterogeneity with at least two distinct forms of USH was raised based
on the differences between families in regard to the severity of hearing loss and vestibular
findings (Davenport et al., 1978; Davenport and Omenn, 1977; Fishman et al., 1983; Forsius et
al., 1971; Hallgren, 1959; Nuutila, 1970). On the basis of phenotypic classification suggested by
Davenport and Omenn (1977), and the clinical features published by the Usher Syndrome
Consortium (Smith et al., 1994), three different USH subtypes have been defined (Table 2). All
USH patients have progressive RP appearing as loss of night vision and restriction of the visual
field, which leads eventually to blindness, while the degree of hearing loss and vestibular
function differs among the three clinical types. An USH1 patient has a profound congenital
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deafness with onset of RP by the first decade, whereas in USH2 the hearing loss is congenital,
from mild to severe. The age at diagnosis of RP in USH2 overlaps with USH1. USH1 and USH2
can be distinguished based on vestibular function. USH1 patients lack vestibular responses which
causes delay in early motor development, whereas USH2 patients are normal in this regard
(Kumar et al., 1984; Möller et al., 1989; Nuutila, 1970). Therefore, children with USH1 are late
to sit and often do not walk before the age of 18 months (Möller et al., 1989). USH1 patients
communicate with sign language, while USH2 patients have residual hearing and benefit from
hearing aids. A third type of Usher syndrome (USH3) was suggested based on the progressive
nature of hearing loss, and RP noted at puberty (Davenport and Omenn, 1977), however, these
patients were estimated to account only for 2% of USH, and USH3 was not accepted as an
established entity (Smith et al., 1994). Some other clinical findings in USH1 patients, such as
cilia anomalies with slow sperm motility and bronchiectasis have been reported (Bonneau et al.,
1993; Hunter et al., 1986).
Table 2. Clinical classification of Usher syndromes
Type Hearing impairment Balance dysfuction Vision loss from retinitis
pigmentosa (RP)
USH1 Profound congenital
hearing loss.
Absent vestibular
responses cause delay
in early motor
development.
Night blindness in infancy or
first decade of life. Legally blind
by early adulthood.
USH2 Mild to severe
congenital hearing loss.
Normal vestibular
responses.
Night blindness in first or second
decade of life. Legally blind by
early adulthood.
USH3 Normal or mild hearing
loss at birth, progressive
hearing loss leads to
moderate to severe
deafness within a few
years or several decades.
Normal or decreased
vestibular responses.
Night blindness in childhood or
teens. Legally blind in early to
mid adulthood. Rate of
progression variable.
5.2. Molecular genetics of USH
At present, ten different loci account for subsets of USH (the Hereditary Hearing Loss
Homepage), of which six genes (USH1B, USH1C, USH1D, USH1F, USH2A, USH3) have been
cloned. Six loci (USH1A-USH1F) correspond to Usher type 1, (Chaib et al., 1997; Kaplan et al.,
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1992; Kimberling et al., 1992; Smith et al., 1992; Wayne et al., 1996; Wayne et al., 1997), and
three loci (USH2A-C) for Usher type 2 (Hmani et al., 1999; Kimberling et al., 1990; Lewis et al.,
1990; Pieke-Dahl et al., 2000). The first locus for Usher type 3 (USH3) was assigned in Finnish
families by Sankila et al. (1995) (Table 3).
Table 3. Molecular classification of Usher syndromes
Locus
Name
Location Gene Protein References
USH1A 14q32 unknown unknown Kaplan et al., 1992
USH1B 11q13.5 MYO7A Myosin VIIA Kimberling et al., 1992; Smith et
al., 1992; Weil et al., 1995
USH1C 11p15.1 USH1C Harmonin Smith et al., 1992; Bitner-
Glindzicz et al., 2000; Verby et
al., 2000
USH1D 10q2 CDH23 Cadherin 23 Wayne et al., 1996; Bolz et al.,
2001; Bork et al., 2001
USH1E 21q21 unknown unknown Chaib et al., 1997
USH1F 10q21 PCDH15 Protocadherin 15 Wayne et al., 1997; Ahmed et
al., 2001
USH2A 1q41 USH2A Usherin Kimberling et al., 1990; Lewis et
al., 1990; Eudy et al., 1998
USH2B 3p23-p24.2 unknown unknown Hmani et al., 1999
USH2C 5q14.3-q21.3 unknown unknown Pieke-Dahl et al., 2000
USH3 3q21-q25 USH3 USH3 Sankila et al., 1995; this study
5.2.1. The USH1 genes
Kaplan et al. (1992) first localized the USH1A gene to chromosome 14q32 in ten families, of
which eight originated from the Poitou-Charentes region in Western France. In the same year,
Smith et al. discovered that 8 French Acadian and 11 British USH1 families were linked to two
different regions in chromosome 11. USH1B was assigned to 11q14 whereas USH1C localized to
11p14, and was restricted to the French Acadian population in Louisiana. The 11q14 locus was
supported in a study by Kimberling et al. (1992), who showed linkage to chromosome 11q in
families from the United States, Sweden, Ireland and South Africa.
In 1995, Gibson et al. identified the defective gene (sh-1) of a naturally occurring deaf
mouse mutant shaker-1 encoding an unconventional murine myosin VIIA (Myo7a) by positional
cloning strategy. Based on the localization of the sh-1 phenotype to the mouse chromosomal
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region homologous to human USH1B, and the role of unconventional myosins in auditory
processes (Gillespie et al., 1993), Myo7a was suggested to be a likely homologue for USH1B.
This led to the cloning of the human homologue, MYO7A, which was shown to be responsible for
USH1B (Weil et al., 1995). MYO7A consists of 48 exons extending over a 100-kb genomic
region, and it has several alternatively spliced forms (Chen et al., 1996). To date, at least 81
different mutations spreading throughout the MYO7A gene have been detected (Adato et al.,
1997; Bharadwaj et al., 2000; Cuevas et al., 1999; Cuevas et al., 1998; Espinos et al., 1998a;
Janecke et al., 1999; Lévy et al., 1997; Liu et al., 1997b; Liu et al., 1997c; Liu et al., 1997d; Liu
et al., 1998b; Weil et al., 1995; Weston et al., 1996). The gene responsible for USH1B has also
been shown to be mutated in two forms of nonsyndromic hearing loss, autosomal recessive
deafness, DFNB2 (Liu et al., 1997d; Weil et al., 1997), and autosomal dominant deafness,
DFNA11 (Liu et al., 1997b). Moreover, in patients with atypical USH, with symptoms similar to
the USH3 phenotype, mutations in the MYO7A gene have been detected (Liu et al., 1998b).
Recently, a gene for USH1C was identified as a PDZ domain-containing protein, named
harmonin (Bitner-Glindzicz et al., 2000; Verpy et al., 2000). The novel gene was identified using
a candidate gene approach by sequencing random cDNA clones from a subtracted mouse library
generated from inner ear sensory areas (Verpy et al., 2000). One clone showed sequence
homology to a gene, encoding the human PDZ domain containing-protein, which mapped to the
USH1C region. In a parallel study by Bitner-Glindzicz et al. (2000), a homozygous 122-kb
deletion, which included most of the genomic region of harmonin, was identified by positional
cloning in patients with severe hyperinsulism, deafness, enteropathy and renal tubular
dysfunction. So far, mutation analyses have indicated altogether six different mutations in
patients (Bitner-Glindzicz et al., 2000; Verpy et al., 2000; Zwaenepoel et al., 2001). Pathogenesis
of USH1C is still unknown, since no animal model exists for the disease.
Harmonin consists of 28 exons of alternatively spliced transcripts with different
expression patterns in various tissues. A functional role for harmonin has been suggested based
on the function of other PDZ domain-containing proteins and the subcellular localization of
harmonin (Bitner-Glindzicz et al., 2000; Montell, 2000; Verpy et al., 2000). PDZ domains are
originally detected in scaffold proteins PSD/SAP90 (postsynaptic density protein), Dlg-A
(Drosophila tumor suppressor), and ZO-1 (tight junction protein) (Montell, 2000; Petit, 2001).
PDZ proteins are known to be involved in protein-protein interactions, to organize multiprotein
41
complexes, for example receptors and ion-channels, at the plasma membrane (Montell, 2000). By
immunofluorescence, harmonin has been detected in mouse sensory hair cells, including the
cytoplasm and the stereocilia bundle (Verpy et al., 2000). Bitner-Glindzicz et al. (2000) detected
low levels of antibody staining in the apical and basal surfaces of the sensory areas in the
developing human ear. No expression was seen in neonatal mouse eyes, although low levels of
anti-harmonin staining was seen on the outer neuroblastic layer of the retina in the developing
human eye (Bitner-Glindzicz et al., 2000). Based on the expression profile in hair cells and the
possible role in stabilizing the hair bundle, Verpy et. al (2000) suggested that harmonin and
myosin VIIA might be components of the same protein complex. As well, harmonin can be
modulating the activity of ion-channels or it can be localizing cytoskeletal and signaling proteins
(Montell, 2000; Verpy et al., 2000).
The fourth locus for USH1 (USH1D) overlaps the locus for nonsyndromic autosomal
recessive deafness (DFNB12) (Chaib et al., 1996), and was assigned to chromosome 10q2 in a
Pakistani pedigree (Wayne et al., 1996). The underlying gene, a novel human cadherin, CDH23,
was identified by positional candidate approach (Bolz et al., 2001) based on a parallel study
determining the gene defect in the orthologous mouse mutant walzer (v) (Di Palma et al., 2001).
Mutations in the orthologous mouse gene, Cdh23, cause disorganization of the stereocilia and
misposition of the kinocilium, supporting the role of Cdh23 as a critical component for the hair
bundle formation. By RT-PCR analysis from several tissues, including retina, Cdh23 was found
to have a broad expression profile. However, by in situ hybridization from neonate cochlea
samples, Cdh23 expression was shown to be restricted to outer and inner hair cells (Di Palma et
al., 2001). Bork et al. (2001) showed CDH23 to be expressed in the human retina by northern blot
analyses. Based on the mutation analyses, USH1D and DFNB12 have been shown to be caused
by altogether 17 allelic mutations of CHD23 (von Brederlow et al., 2002; Bolz et al., 2001; Bork
et al., 2001). In general, classical cadherins are involved in cell-to-cell adhesions and cell-
extracellular interactions. Probably, CDH23 mediates similar functions. Also, it has been shown
that in the presence of a calcium chelator, the hair cell stereocilia tip-links are disrupted. In the
absence of calcium, cadherins undergo proteolysis, which indicates that CDH23 may be
associated with these links (Petit, 2001).
The fifth identified locus for USH1, USH1E, was assigned to chromosome 21q21 by
Chaib et al. (1997). Using homozygosity mapping in a consanguineous family from Morocco,
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USH1E was mapped to a delimited 15-cM interval. The gene underlying USH1E has not been
cloned so far.
USH1F was assigned to chromosome 10q21 (Wayne et al., 1997) in a region of conserved
synteny to mouse chromosome 10 containing a novel protocadherin gene, Pcdh15. The deafness
and balance disorder in a mouse mutant, ames waltzer (av), is caused by a recessive av mutation
of the Pcdh15 gene (Alagramam et al., 2001a), and av was thereby suggested as a mouse model
for USH1F, although no retinopathy had been reported in these mice. Subsequent protein
sequence homology searches of overlapping BAC clones in the USH1F region indicated the
human orthologue, PCDH15, which spanned approximately 1.6 Mb of genomic DNA. On a
northern blot, a variety of putative PCDH15 transcripts were identified in several tissues,
including retina (Ahmed et al., 2001). By immunohistochemistry, PCDH15 has been shown to be
expressed especially in the synaptic and nerve fiber layers of retina, whereas in the human fetal
cochlea, PCDH15 expression was detected in the hair cells, in the supporting cells, and in the
spiral ganglion cells (Alagramam et al., 2001b). In the following mutation analysis of 33 exons of
PCDH15, four different mutations were indicated in two Pakistani families, in a Hutterite family
from Alberta, and Indian families with USH1F (Ahmed et al., 2001, Alagramam et al., 2001b).
According to the findings of abnormal supporting cells and stereocilia of both outer and inner hair
cells in av mice, PCDH15 has been proposed to have a possible role in maintaining the structure
of the stereocilia bundles of the apical surface of hair cells (Alagramam et al., 2001a; Alagramam
et al., 2001b).
5.2.2. The USH2 genes
In 1990, Kimberling et al. and Lewis et al. mapped the first gene for USH2 on chromosome
1q32-q44. Later, this gene, USH2A, comprising 21 exons, was identified by positional cloning
from BAC subclones and a retina cDNA library as a putative extracellular matrix protein,
usherin, with laminin epidermal growth factor and fibronectin type III motifs (Eudy et al., 1998;
Weston et al., 2000). In contrast to the USH1 genes, immunohistolabelling suggests that usherin
has a broad but not ubiquitous tissue distribution, and is a component of basement membranes in
the retina, in the lens capsule, in the Bruch's layer between the RPE and the choroid layer, and in
the cochlea (Bhattacharya et al., 2002). Thus, the molecular pathogenesis of USH2A may be
different from that of USH1 (Petit, 2001).
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In the initial mutation analysis, three novel mutations were detected, of which one,
2299delG (named also 2314delG) leads to a premature stop codon within a crucial region in the
laminin epidermal growth factor motif of USH2A (Eudy et al., 1998). Additional mutation
searches of USH2A patients (Adato et al., 2000; Dreyer et al., 2000; Weston et al., 2000, Leroy et
al., 2001) and patients with recessive retinitis pigmentosa without hearing loss (Rivolta et al.,
2000), as well as USH3-like patients with late onset of progressive deafness and variable
vestibular dysfunction (Liu et al., 1999b) indicated altogether 33 distinct disease-causing
mutations.
The 2299delG mutation in the USH2A gene seems to be extremely common in many
populations, in southern and northern Europe, in South America, in South Africa and in China,
and may account for a substantial proportion of retinitis pigmentosa in humans (Beneyto et al.,
2000; Dreyer et al., 2001; Eudy et al., 1998; Leroy et al., 2001; Liu et al., 1999b; Rivolta et al.,
2000; Weston et al., 2000). In the haplotype analyses of 116 unrelated patients with USH2 from
14 countries, Dreyer et al. (2001) found that all 2299delG chromosomes are in complete
association with one specific core haplotype. Their data strongly suggest that the widespread
geographic distribution of 2299delG is the result of an ancestral mutation that has spread
throughout Europe as a result of migration, instead of being a mutational hotspot in USH2A
(Eudy et al., 1998; Liu et al., 1999b).
Although most USH2 families show linkage to 1q41, evidence for genetic heterogeneity
was showed in non-consanguineous families from northern European origin (Pieke Dahl et al.,
1993) and in one consanguineous family from Tunisia (Hmani et al., 1999). The locus for
USH2B was localized to chromosome 5q (Pieke-Dahl et al., 2000), whereas the Tunisian variant
USH2C was assigned to chromosome 3p23 (Hmani et al., 1999). So far, the genes coding USH2B
and USH2C have not been identified.
5.2.3. Usher syndrome type 3 (USH3)
Nuutila first described patients with retinitis pigmentosa and progressive sensorineural hearing
loss, the familial dystrophia retinae pigmentosa - dysacusis syndrome (DRD), which began
during puberty, in 3% of the Finnish USH patients (Nuutila, 1968; Nuutila, 1970). Although
several other studies of progressive hearing loss in patients have been published in Finland
(Karjalainen et al. 1983, Karjalainen et al., 1989) and elsewhere (Davenport and Omenn, 1977;
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Gorlin et al., 1979; Gröndahl and Mjöen, 1986; Karp and Santore, 1983), the third clinically and
genetically distinct entity of USH was not generally accepted (Smith et al., 1994) until Sankila et
al. (1995) excluded by linkage four other chromosomal sites, to which USH had been previously
mapped (Kaplan et al., 1992; Kimberling et al., 1992; Kimberling et al., 1990; Lewis et al., 1990;
Smith et al., 1992), and assigned the USH3 locus to chromosome 3q21-q25 by linkage in ten
Finnish multiplex affected families. Twelve out of twenty of the USH parental chromosomes
were found to share a common ancestral haplotype comprising alleles at five marker loci,
suggesting enrichment of a major mutation in Finland. Multipoint analyses assigned USH3 within
the 5-cM genetic region between the polymorphic DNA markers D3S1555 and D3S1279.
Moreover, Pakarinen et al. (1995a) showed that USH3 with progressive hearing loss is the most
common form of USH in Finland and covers 40% of all the studied 229 USH cases. These
Finnish patients originated mainly from the eastern part of Finland suggesting enrichment of the
putative USH3 mutation. Later, other USH families showing linkage to the USH3 region have
also been reported from the US and Sweden (Kimberling et al., 1995), Spain (Espinos et al.,
1998b), Israel (Adato et al., 1999), and Italy (Gasparini et al., 1998).
5.2.3.1. Clinical manifestations of USH3
Usher syndrome type 3 (USH3; MIM No. 276902) is an autosomal recessively inherited disorder
characterized by congenital, childhood or adulthood onset of progressive hearing loss,
progressive retinitis pigmentosa and decreased vestibular dysfunction in some patients. The main
clinical features of USH3 are summarized on the basis of detailed clinical analysis of 42 Finnish
USH3 patients from 23 families (Pakarinen et al. 1995b; Pakarinen et al., 1996; Pakarinen, 1997),
whose diagnosis was confirmed by earlier linkage and haplotype analysis (Sankila et al., 1995;
see also this study). The clinical features of USH3 were described as follows: hearing impairment
is usually postlingual and develops by the age of eight years, some cases of congenital or
adulthood onset also occurs. The hearing loss is progressive, sensorineural and cochlear resulting
in moderate to severe deafness within a few years or decades. The typical audiometric curve is
slightly down sloping or U-shaped. Usually patients benefit from hearing aids and communicate
verbally, but later as the hearing loss progresses, the method of communication is sign language
in conjugation with lip reading. Cochlear implantation is a suitable treatment for USH3 patients
with profound hearing loss. The diagnosis for retinitis pigmentosa is made usually by
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electroretinogram (ERG) and typical fundus findings; thin vessels, granular pigmentation in the
midperiphery of the retina, clusters of pigment starting from the nasal peripheric retina or rough
pigment epithelium. RP is diagnosed at the mean age of 17 years. The symptoms of night-
blindness, followed by mid peripheral visual field defects, lead to narrowed visual fields and to
slowly progressive tunnel vision at a mean age of 30 years. The progression of RP by the age of
20-30 years results in a severe visual handicap. High degree hypermetropia together with
concurrent astigmatism has been found in 40% of the patients. Patients have either normal or
decreased vestibular function. Mental retardation or psychiatric illness have been reported in
USH patients (Carvill, 2001; Hallgren, 1959; Karjalainen et al., 1983; Nuutila, 1970; Sharp et al.,
1994; Waldeck et al., 2001), but they are unlikely to be part of the USH, since non-USH members
of the families also had similar mental symptoms. Pakarinen et al. (1995b) reported three USH3
families with lowered intelligence and psychiatric symptoms or schizophrenia-like psychosis, but
most USH3 patients had normal intelligence.
Based on the study by Shinkawa and Nadol (1986), the histopathology of the inner ear of
an USH3 patient with progressive loss of hearing and vision showed abnormalities in the cochlea,
such as loss of hair cells in the basal turn of the organ of Corti, widespread neural degeneration
accompanied by severe loss of spiral ganglion cells and degeneration of supporting cells filled
with vacuoles of degenerative cytoplasmic proteins.
On clinical grounds, an early and accurate diagnosis, as well as differentiation of USH3
from the other USH types, is difficult. RP does not differ from the other Usher types, and the type
of hearing loss and vestibular function are the distinguishing features. Also, the progression of
hearing loss is sometimes difficult to detect, since it can be prelingual, slow, or late onset
(Pakarinen et al., 1995b; Pakarinen, 1997).
5.3. Shaker-1 as a mouse model for pathogenesis of USH1B
Knowledge of the pathogenesis of heterogeneous USH has been mainly obtained from the
anomalies observed in deafness mouse models. Moreover, identification of genes involved in
human deafness has been facilitated by first cloning the causative orthologous mouse genes
(Alagramam et al., 2001a; Bork et al., 2001; Gibson et al., 1995; Verpy et al., 2000). The
expression patterns of the disease gene, and subcellular localization of the encoded protein
probably have been studied most extensively in the sh-1 mouse, which was first described already
46
in 1929 by Lord and Gates. Sh-1 suffers from symptoms associated with inner-ear defects:
vestibular dysfunction causing hyperactivity, head-tossing and circling, combined with
neuroepithelial abnormalities and degeneration of the organ of Corti due to a defective myosin
VIIA gene (Gibson et al., 1995; Weil et al., 1995). Both the human USH1 and the mouse sh-1
phenotypes involve sensorineural hearing loss and vestibular dysfunction. In the mouse cochlea
and vestibular tissues, Myo7a is expressed exclusively very early in sensory hair cell
development (el-Amraoui et al., 1996). It colocalizes with cross-links between stereocilia, to the
cuticular plate, and between the adherens junction and the cuticular plate, known as pericuticular
necklace (el-Amraoui et al., 1996; Hasson et al., 1995; Hasson et al., 1997a; Hasson et al., 1997b;
Self et al., 1998). In the retina, Myo7a is present in both the RPE and the photoreceptor cells,
especially in the connecting cilium joining the inner and outer segments of the photoreceptors (el-
Amraoui et al., 1996; Hasson et al., 1995; Liu et al., 1997a; Liu and Willems, 2001). The
complete sequence and at least seven different mutations in sh-1 encoding Myo7a have been
determined in detail (Hasson et al., 1997b; Mburu et al., 1997).
5.3.1. Myosin VIIA function in cochlea
The exact role of myosin VIIA in sensory hair cell function is still unknown while the study by
Self et al. (1998) with three sh-1 mutants has expedited the understanding of both the
development and function of cochlear hair cells. Most of the sh-1 mutants show normal growth
and heights of stereocilia, but the kinocilium is misplaced, and the stereocilia bundles are
progressively disorganized leading to degeneration of hair cells (Gibson et al., 1995; Self et al.,
1998). The sh-1 mice exhibit degeneration of the organ of Corti and the afferent neurons during
the first weeks after birth (Hasson et al., 1995). According to Hasson et al., the defect lies within
the hair cells, and the degeneration of the neurons is secondary.
The location of myosin VIIA along the length of stereocilia and to the lower end, near the
bases of stereocilia in hair cells (Hasson et al., 1995; Hasson et al., 1997a; Hasson et al., 1997b;
Self et al., 1998), is consistent with the formation of a protein complex, which joins adjacent
stereocilia to their neighbours and gives a precise arrangement of the stereocilia. Myosin VIIA
has been proposed to anchor these ankle links to the actin cytoskeleton through a complex of
ubiquitous transmembrane protein, vezatin, and a component of the ankle link protein, a PDZ
domain-containing protein (Küssel-Andermann et al., 2000) (Figure 3). Recently, a gene
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encoding a new PDZ domain-containing protein, harmonin, has been discovered to underlie
USH1C (Bitner-Glindzicz et al., 2000; Verpy et al., 2000). Interaction of vezatin with myosin
VIIA in controlling the tension of stereocilia may be mediated by Ca2+-dependent cell-cell
adhesion molecules, for example cadherins, which also may be involved in binding the lateral
links or tip links of stereocilia (Küssel-Andermann et al., 2000; Müller and Littlewood-Evans,
2001). Interestingly, mutations in cadherin 23 (CDH23) and protocadherin 15 (PCDH15) have
been shown to underlie human USH1D, DFNB12, and USH1F (Ahmed et al., 2001; Alagramam
et al., 2001b; Bolz et al., 2001; Bork et al., 2001). The exact function of these anchoring proteins
is not clear, although it has been suggested that they have an important role in controlling the
location of myosin VIIA along the stereocilia either by preventing myosin VIIA from moving up
actin filaments or inhibit the enzymatic activity of myosin VIIA (Hasson et al., 1997a).
Mutations in Myo7a have been demonstrated to slack the gating springs in resting
stereocilia and to close the transduction channels (Richardson et al., 1997). Thus, a possible role
for myosin VIIA in adjusting the tension of the tip-link and/or transduction channel complex has
been suggested (Steel and Kros, 2001).
Stereocilia rootlets in the hair cell are anchored by the actin-rich structure, cuticular plate.
The pericuticular necklace of the hair cell is rich in membrane vesicles and it can serve as a
reservoir of components needed in cuticular plate and stereocilia (Hasson et al., 1997a). Self et al.
(1998) demonstrated that sh-1 mutants show irregular bulges of the cuticular plate as they are
interrupted by areas of vesicle-rich cytoplasm. A possible role for myosin VIIA at adherens
junctions is to stabilize the cuticular plate linked to rootlets of stereocilia through the interactions
with vezatin, which also localizes at the junctions between hair cells and supporting cells (Küssel-
Andermann et al., 2000). Furthermore, myosin VIIA may be involved in microtubule-bound
vesicular traffic or membrane uptake events in the pericuticular necklace supported by the
findings that the hair cells of sh-1 mice have a defect in aminoglycoside uptake (Richardson et
al., 1997).
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Figure 3. Schematic picture of apical surface of a hair cell and its stereocilia. Localization of myosin VIIA,
harmonin (speculative), and vezatin (speculative) is shown. Source García-Añoveros and Corey (1997), and Steel
and Kros (2001).
5.3.2. Myosin VIIA function in retina
In retinitis pigmentosa, the sensory cells in the retina eventually die (Rattner et al., 1999). While
USH1B patients manifest progressive RP leading to blindness, none of the known sh-1 allelic
mutants appear to develop retinopathy (Gibson et al., 1995; Weil et al., 1995). The reason why
retinal degeneration is observed only in humans is still unknown. The mutations in MYO7A
underlying USH1B may be different from those found in the mutant mouse Myo7a, and the
genetic background may play an important role in the severity of the disease (Self et al., 1998).
Recently, Libby and Steel (2001) showed evidence for a physiological abnormality in the retinas
of several different Myo7a mutant mice by ERG. As in humans associated with USH1 (Seeliger
et al., 2000), mutations in mouse Myo7a were found to lead to decreased ERG a-wave- (resulting
from the photoreceptors' response to light) and b-wave (resulting from retinal interneurons
activated by photoreceptors) amplitudes, suggesting that photoreceptors in mutant mice are not
responding properly to light. However, the retinal dysfunction seems to be similar in all USH1
cases, since no statistically significant difference in visual function between USH1 patients with
or without pathogenic MYO7A mutations was seen in the study by Bharadwaj et al. (2000).
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In a study of myosin VIIA expression in developing mouse and human eye, myosin VIIA
has been immunolocalized in the apical surface of RPE and the photoreceptor cells (el-Amraoui
et al., 1996; Hasson et al., 1995; Liu et al., 1997a). In the first study of retinal phenotype
associated with mutant myosin VIIA, Liu et al. (1998a) showed that myosin VIIA is required for
correct distribution of the melanosomes in the sh-1 mouse RPE. However, they concluded that
this organelle transport in itself does not seem to be critical for retinal viability, since other mice
with melanosome abnormalities do not normally undergo retinal degeneration.
Titus (1999) studied myosin VIIA distribution within apical microvilli of RPE in myosin
VIIA knockout amoebae Dictyostelium discoideum, and suggested that myosin VIIA has a
possible role in phagocytosis of the outer segments of exfoliated photoreceptors. Phagocytosis
has not reported in sh-1 mice, however, the mutant Dictyostelium discoideum showed an 80%
decrease in the phagocytosis of particles, such as yeast, bacteria or latex beads. The defect in
phagocytosis is neither because of altered particle binding nor inability to form actin-filled
phagocytic cups, rather it appears to lie in actin-dependent particle internalization, where myosin
VIIA is suggested to play an important role (Titus, 1999).
In photoreceptors, myosin VIIA localizes in the connecting cilium joining the inner and
outer segments (Liu et al., 1997a; Liu and Williams, 2001). In addition, myosin VIIA has been
detected in the synaptic endings of human photoreceptor cells, where it could be involved in the
formation and trafficking of the vesicle complexes (el-Amraoui et al., 1996). The appearance of
myosin VIIA in the connecting cilium of photoreceptors suggests that it might be involved in the
visual cascade by transporting phototransductive proteins, such as opsin, through the connecting
cilium into the outer segment of the photoreceptor. This is supported by electron
immunomicroscopic studies of sh-1 mice photoreceptor cells, which showed that the mutant
Myo7a results in abnormal accumulation of opsin in the connecting cilium (Liu et al., 1999a).
However, Liu et al. did not detect a complete blockage of transport from the site of opsin
synthesis in the inner segment to the outer segment. Mutant myosin VIIA did not affect either the
distribution of other outer segment proteins, indicating that the abnormal accumulation of opsin is
not the result of a general defect affecting the transport of all proteins (Liu et al., 1999a). Further
work by Liu and Willems (2001) showed that coincident onset of expression of opsin and myosin
VIIA in the mouse cilium was consistent with the role of myosin VIIA in the transport of opsin.
Abnormal opsin transport over a prolonged period thus might contribute to blindness in USH.
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AIMS OF THE PRESENT STUDY
The purpose of this study was to identify the gene and the disease causing mutation(s) underlying
Usher syndrome type 3 (USH3) to provide a basis for understanding the molecular pathogenesis
of the disease and to enable exact and even presymptomatic diagnosis of the disease.
This work was initiated when the chromosomal localization of USH3 had been assigned to
chromosome 3q21-q25 (Sankila et al., 1995). Thereafter, the positional cloning strategy was
undertaken to:
1. Further delineate the chromosomal region of USH3 by genetic mapping using an extended
number of families with a denser map of markers.
2. Establish a physical map across the critical region and construct a contig of genomic clones
providing tools for isolation of gene sequences.
3. Construct a transcript map for the characterization of positional candidate genes.
4. Identify the USH3 gene among the candidate genes, and characterize the disease causing
mutations.
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MATERIALS AND METHODS
1. USH3 families and control individuals
In addition to the 10 multiplex USH3 families studied by Sankila et al. (1995), blood samples
from 22 Finnish families, of which 4 were multiplex and 18 were simplex, three non-Finnish (1
Italian and 2 Spanish) multiplex families and two patients (1 English simplex patient, and 1 from
Belgium with autosomal dominant hearing loss assigned to the same chromosomal region) were
included in this study. All the Finnish USH3 patients were diagnosed and ascertained by L.
Pakarinen, and the clinical findings have been described elsewhere (Pakarinen et al., 1995b;
Pakarinen et al., 1996; Pakarinen, 1997; Sankila et al., 1995). Clinical and genealogical data of
the Italian and Spanish families have been reported elsewhere (Espinos et al., 1998b; Gasparini et
al., 1998).
Control DNA samples from 200 anonymous blood donors from Eastern (high prevalence
of USH3), Western and Southern Finland (low prevalence of USH3) were provided by the
Finnish Red Cross Blood Transfusion Service. Moreover, a total of 51 grandparents of Centre
d'Etude du Polymorphisme Humain (CEPH) families were also studied as control.
2. Genealogical studies
Genealogical studies of the 32 Finnish USH3 families were performed to determine the parental
and grandparental birthplaces of the patients. In addition, some families were traced back in
search for common ancestors.
3. Genotyping and linkage analyses
Genomic DNA was extracted from leukocytes contained in 10-20 ml of peripheral venous blood
using standard methods. The families were typed with a total of nine polymorphic microsatellite
markers from Genéthon (Dib et al., 1996), Cooperative Human Linkage Center (Sheffield et al.,
1995), and the published polymorphism for the type 1 angiotensin II receptor gene (AGTR1)
(Davies et al., 1994). Polymorphic markers were amplified in a PCR-reaction of a total volume of
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10 µl with 30 ng of genomic DNA. The amplification was carried out during 30 cycles of 94oC
45 sec, and 55oC 45 sec, followed by a final extension at 72oC for 4 min. The alleles were
analyzed in 6% polyacrylamide, 7 M urea denaturing gels, and visualized by silver staining
(Bassam et al., 1991) or 32P-dATP labelled autoradiography.
Pairwise linkage analysis was carried out using the MLINK program of the LINKAGE
program package (Lathrop et al., 1984). The allele frequencies were calculated from 43 normal
parental chromosomes. The USH3 disease frequency was set to 0.001, and complete penetrance
and sex average recombinations were assumed. The multipoint linkage analysis was carried out
using the program VITESSE (O'Connell and Weeks, 1995). The intermarker distances used in the
VITESSE and the DISMULT analyses (see below) were estimated based on the published genetic
data (Dib et al., 1996; Sankila et al., 1995), and the physical and haplotype mapping results
obtained in this study.
4. Linkage disequilibrium and haplotype analyses
Association analysis for multiple loci simultaneously was carried out using the program
DISMULT version 2.1 (Terwilliger, 1995), and the confidence interval was calculated as Zmax
(±)3 lod units. The significance of the linkage disequilibrium was measured by the single locus
association analysis program DISLAMB (Terwilliger, 1995), in which the analysis is based on
the parameter λ  that is equal to the proportion of increase of a certain allele in disease
chromosomes, relative to its population frequency. The confidence intervals for λ were calculated
as 1-lod units. In all allelic association calculations, the parental non-USH3 associated alleles
were used as controls.
For the estimation of genetic distances between the close markers and USH3, Luria-
Delbrück-based calculation was used (de la Chapelle, 1993; Hästbacka et al., 1992; Lehesjoki et
al., 1993). The number of generations since founding (g) was assessed to 10-200, the mutation
rate (µ) of the USH3 locus was set to 1 x 10-6, and the USH3 gene frequency (q) was estimated to
be 0.003. Allelic association was calculated according to the formula pexcess= (paffected-pnormal)/(1-
pnormal), where p equals the marker allele frequency. The recombination fraction between USH3
and the marker locus, the theta value (θ), was calculated using the formula pexcess = (1-µgq-1)(1-
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θ)g, where (1-µgq-1) denotes the proportion of USH3 chromosomes carrying the same ancestral
mutation.
Haplotypes of the USH3 families were constructed manually, assuming the minimum
number of recombinations in each family.
5. Isolation of genomic clones
A panel of mega yeast artificial chromosome (YAC) clones positive for the originally linked
markers across the USH3 region (Sankila et al., 1995) were provided by the Centre d'Etude du
Polymorphisme Humain (CEPH) in Paris. The clones were cultured, total yeast DNA was
extracted and stored in agarose beads.
The ESTs and STSs (see below) present on the YACs were used for screening of the
bacterial artificial chromosome (BAC) library (Research Genetics Inc., Huntsville, AL) by PCR.
The positive colonies were cultured overnight in Luria Broth media containing the appropriate
antibiotic, and DNA was extracted using Qiagen's standard protocol for Plasmid Midiprep (tip
100) kit. NotI-digested BAC DNA was subjected to pulsed-field electrophoretic separation to
determine the insert sizes in the clones, and the separated fragments were visualized in UV-light.
The sizes of individual inserts were determined relative to a high molecular weight λ ladder (New
England BioLabs).
6. EST and STS mapping
The YAC and BAC clones were screened for the presence or absence of ESTs and STSs obtained
from the Chromosome 3 Database (The University of Texas Health Science Center at San
Antonio; http://mars.uthscsa.edu; (Naylor et al., 1996)), the Genome Data Base (Cuticchia et al.,
1993), the database at the Whitehead Institute for Biomedical Research/MIT Center for Genome
Research (http://www-genome.wi.mit.edu), and the National Center for Biotechnology
(http://www.ncbi.nlm.nih.gov/SCIENCE96/ and /genemap98/) by PCR amplification using the
conditions described earlier. The PCR primers used in the physical mapping were designed using
the program Primer3 (www.genome.wi.mit.edu/cgi-bin/primer/primer3_www.cgi).
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New STSs were generated from the BAC-ends by sequencing with T7 and SP6 primers.
The sequences obtained were screened against a library of repetitive elements using the program
Repeat  Masker2 at  the Universi ty of  Washington Genome Center
(http://www.genome.washington.edu/UWGC/). Primer pairs were designed from the end-
sequences, except for when the sequence contained repetitive elements. The STSs generated from
the BAC-ends were used to further screen clones from the BAC libraries and to determine the
orientation of BACs in the contigs by PCR.
7. Generation and mapping of novel polymorphic markers
Novel polymorphic (CA)n-repeat markers were isolated by subcloning BAC clones into the
pUC18 vector (Pharmacia, Biotech). BAC DNA was digested with RsaI, ligated to SmaI-cut
pUC18 vector, transformed into E. Coli SURE competent cells (Stratagene), and plated onto
selective agar plates. Putative polymorphisms were screened with [γ-32P]dATP radiolabelled
(GT)16 oligonucleotide probes. Double positive clones were selected, and DNA was extracted
using Qiagen's Plasmid Miniprep Kit following the manufacturer's protocol. Positive clones were
sequenced using T7 and SP6 primers. Primers flanking an identified (CA)n-repeat were designed
and used in genotyping by PCR. The allele sizes and frequencies for the novel markers were
calculated from 48 non-USH3 associated chromosomes.
Through genomic sequencing of a positional candidate gene, NOPAR, (see below), the
novel single nucleotide polymorphisms, TSNP1 and RSNP2, were identified. Intronic forward
and reverse primers were designed and used to genotype the USH3 families by PCR. The alleles
were detected either by direct sequencing or by SSCP analysis in 0.7 x MDE gel for 18 h, 5 W at
room temperature, and they were visualized by silver staining.
8. Genetic mapping of the USH3 mouse homologue
The mouse EST sequence fragment r75057, homologous to the 3' UTR of human profilin-2
(PFN2) (EMBL accession no. R75057), was used in linkage analysis of the European
Collaborative Interspecific Backcross (EUCIB) mapping resource comprising 982 backcross
progeny (Breen et al., 1994). DNA samples were provided by the MRC HGMP Resource Centre
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(Hinxton, Cambridge). For PCR reactions, 2 ng of mouse genomic DNA was used as a template
for a 25-µl PCR reaction. The cycling conditions were 94oC for 4 min, followed by 35 cycles of:
93oC 3 sec, 53oC 10 sec and 72oC 15 sec. For SSCP analysis, PCR samples were
electrophoresed overnight at 4oC on an 8% non-denaturing polyacrylamide gel, and the alleles
were visualized using silver staining. The linkage analysis was computed using the MBx database
supporting EUCIB (Breen et al., 1994).
9. Large-scale sequencing and contig assembly
The complete genomic sequence of the USH3 region was constructed by shotgun cloning of the
BAC clones. Shotgun libraries were prepared and plasmid DNA was extracted by Seqwright
(Houston, TX) and GATC GmbH Shotgun Library Construction services (Konstanz, Germany).
The individual BAC subclones were sequenced from both directions using a PE9700 Thermal
Cycler (Perkin Elmer).
To assemble the genomic contigs, all sequence readings were edited and filtered using the
GASP software (http://www.genome.washington.edu/UWGC/analysistools) in a UNIX-based
system. The genomic 149-kb contig was assembled based on the fragment order on the physical
map using the program Sequencer 3, whereas the 207-kb contig was assembled using Phil
Green's Phred, Phrap and Consed sequence assembly programs (http://www.phrap.org). To find
additional BACs or P1-derived artificial clones mapping in the same region, the contig sequences
were compared with High-Throughput Genome Sequence (HTGS) and Genomic Survey
Sequence (GSS) databases at NCBI. The orientation of the contigs from centromere to telomere
was determined based on STS mapping.
10. Database analyses
The assembled genomic sequence contigs were screened for repetitive elements, and introduced
to BLAST (http://www.ncbi.nlm.nih.gov/BLAST) programs against different databases, as well
as to HINT (Human Index for Nonredundant Transcripts) (http://pandora.med.ohio-
state.edu/HINT), to UNIGENE (http://www.ncbi.nlm.nih.gov) and to TIGR's Human Gene Index
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(http://www.tigr.org/tdb/hgi). To compare orthologous mouse genomic sequences, homology
searches were performed using Celera Assembled and Annotated Mouse Genome
(http://publication.celera.com/). The gene and exon predictions were carried out using programs
GRAIL (Uberbacher and Mural, 1991) and GENSCAN (Burge and Karlin, 1997), as well as
automated sequence annotation softwares Genotator (Harris, 1997) and NIX
(http://www.hgmp.mrc.ac.uk).
11. Isolation and mutation analysis of the positional candidate genes
Positional candidate genes were isolated as full-length cDNAs with rapid amplification of cDNA
ends (RACE-PCR) and RT-PCR using the Marathon Ready Human Retina cDNA library and
human placenta or retina RNA preparations. Primers for the mutation analyses of the novel genes
were designed and used in the PCR amplification. The PCR fragments were analyzed by SSCP
analysis or by direct sequencing of all exonic regions with adjacent splice sites from patients'
genomic DNA and when possible, from total and poly(A) RNA from EBV-transformed
lymphoblasts extracted from two USH3 patients, two carriers, and two normal individuals. The
SSCP alleles were separated in 0.7 x MDE gel for 18 h, 5 W at room temperature and visualized
by silver staining. The purified amplification products (PCR purification Kit, Qiagen) were
sequenced using ABI 377-sequencer (Perkin Elmer).
12. Isolation and characterization of the USH3 gene
The predicted exons and the EST 35f2 were combined by PCR amplification from human retina
cDNA and Marathon Ready Human Retina cDNA library (Clontech) using the interexon, 5'- and
3'-UTR primers. The exon-intron boundaries were established comparing the USH3 cDNA with
the genomic sequence obtained from databases. For the mutation analysis, the genomic fragments
encompassing USH3 exons were amplified with intronic primers. Mutations were screened by
direct sequencing or by SSCP according to the protocol described earlier.
Predictions for regulatory elements and promoters at the 5'-flanking genomic sequences of
USH3 were performed using MatInspector/TRANSFAC and Neural Network Promoter Input
programs at Search Launcher (http://searchlauncher.bcm.tmc.edu/). Protein predictions were
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carried out using softwares PIX (http://www.hgmp.mrc.ac.uk) and LASERGENE (DNASTAR
Ltd, UK), and programs Tmpred (http://www.ch.embnet.org/software/TMPRED_form.html),
SignalP (http://www.cbs.dtu.dk/services/SignalP/) and PSORTII (http://psort.nibb.ac.jp/).
13. Northern hybridizations
For northern blots, 2 µg of poly(A)RNA or 10 µg of total RNA were extracted from lymphoblasts
of USH3 patients, carriers, and controls, and the samples were electrophoresed on a 1%
denaturing formaldehyde-agarose gel, followed by transfer to a nylon membrane. The membrane
and the commercial human or mouse multiple tissue northern blots were hybridized with
[α32P]dCTP random-labelled cDNAs derived from different positional candidate genes as probes
according to manufacturer's protocols. The blots were hybridized with an β-actin probe as a
control.
14. In situ expression studies
A 262-bp PCR fragment homologous to USH3 was amplified from Marathon Ready Mouse Brain
cDNA library (Clontech) and cloned into a pGEM-T Easy vector (Promega) according to the
manufacturer's instructions. The synthesis of cRNA probes and in situ hybridization were done as
described by Wilkinson and Green (1990). The 4% paraformaldehyde –fixed paraffin sections
from an embryonic day 16 mouse and from dissected adult mouse eyes and inner ears were
hybridized with in vitro transcribed 35S-labelled antisense and control-sense cRNA probes.
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RESULTS AND DISCUSSION
1. Genetic refinement of the USH3 locus by linkage analyses (I)
The efforts towards the positional cloning of the USH3 gene were started based on the initial
assignment of USH3 to a 5-cM interval between the markers D3S1555 and D3S1279 by linkage
analyses in ten USH3 families (Sankila et al., 1995). The panel of families genotyped was
enlarged from 10 to 32 families with nine polymorphic DNA markers across the critical region.
Two-point linkage analysis with USH3 and each of the markers showed the highest lod score of
9.84 at D3S1299 (θ = 0.0) between markers D3S1555 and D3S3625. In a six-point linkage
analysis between USH3 and five linked marker loci D3S1555, D3S1308, D3S2401, D3S1299, and
D3S3625, a maximum six-point lod score of 13.89 was obtained at D3S1299 assigning USH3 to a
4-cM region between D3S1555 and a novel marker D3S3625.
2. Further refinement of the USH3 locus to a 1-cM region by linkage dis-
equilibrium (I, II)
To further refine the localization of the USH3 gene, linkage disequilibrium analysis was
performed utilizing the program DISMULT with nine markers at intermarker distances (in
kilobase pairs) of cen-D3S3661-(500)-D3S1555-(1000)-D3S1308-(1000)-D3S2401-(1000)-
D3S1299-(1000)-D3S3625-(1000)-D3S1594-(500)-D3S1279-(2000)-D3S1746 -tel. Significant
linkage disequilibrium was detected with all the markers analyzed, and the maximum likelihood
estimate (Zmax = 57.02) for the location of USH3 was obtained between markers D3S3625 and
D3S1594  at 0.4 cM proximal to D3S1594. As the confidence interval was calculated as Zmax (±3)
lod units, the USH3 genomic region was shown to span ~1.3 cM around the loci D3S3625 and
D3S1594.
For quantitative estimations of genetic distances between USH3 and five close marker loci
D3S2401, D3S1299, D3S3625, D3S1594, and D3S1279, calculations based on Luria-Delbrück
formula were performed. The mutation age was estimated based on an observation of a conserved
ancestral disease-associated haplotype spanning ~6.5 cM around the USH3 locus (see below), and
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of geographical distribution of the grandparental birthplaces in the middle parts of Finland.
Assuming 20 generations (g) of expansion of the USH3 mutation, the USH3 gene frequency (q)
of 0.003, and a mutation rate (µ) of 1 x 10-6, the Luria-Delbrück-based analysis suggested that
USH3 lies within less than 0.5 cM from the loci D3S3625 and D3S1594. The calculated Pexcess
values for markers D3S1299, D3S3625, and D3S1594 were as 0.83, 0.94, and 0.94, respectively.
Finally, consistent with the above results, the single locus association program DISLAMB
(Terwilliger, 1995) with three novel microsatellites, 25B8CA1, 25B8CA2, and 107G19CA7, (see
below), detected the strongest allelic association at the locus 107G19CA7 (λ-value 0.973 with p-
value < 10-15) placing USH3 between the markers D3S1299 and D3S3625.
3. Haplotypes suggest only one ancestral USH3 mutation in Finland (I)
The haplotype analysis by Sankila et al. (1995) suggested a major ancestral founding USH3
haplotype in Finland. Of the 20 parental haplotypes studied, 12 chromosomes carried the same
alleles at five marker loci. However, in one family, the disease haplotype of the mother differed
from the major USH3 haplotype suggesting another mutation segregating in the family. Based on
these results, the disease-associated haplotypes were constructed in the 20 original and 57
additional USH3 chromosomes with nine marker loci. The ancestral haplotype was present in 37
of 77 USH3 bearing chromosomes spanning ~6.5 cM around the USH3 locus. The other
haplotypes suggested historical crossovers placing USH3 between the markers D3S1299 and
D3S3625, none of the haplotypes being present in non-USH3 chromosomes. With this denser
map of markers, the dissimilar haplotype previously observed in one of the families (Sankila et
al., 1995), was found identical to the ancestral haplotype at markers D3S3625 and D3S1594, and
was thus thought to represent the major mutation. A similar haplotype was observed in another
novel family as well. According to historical recombinations suggested by haplotypes, the
location of the Finnish USH3 mutation could be narrowed to an approximately 1-cM interval
between the markers D3S1299 and D3S3625.
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4. Construction of the physical map across the critical USH3 region
4.1. Novel STSs and ESTs allow joining of the genomic clones into contiguous contigs and
refining of the critical region (I, II)
In order to map new polymorphisms and to identify positional candidate genes for USH3, we
constructed a genomic YAC contig across the region between the markers D3S1308 and
D3S1279. Altogether 20 partly overlapping CEPH megaYACs covering approximately an 8.5-cM
genomic region were ordered based on the known genetic order of the polymorphic markers used
in the linkage studies. Seven new polymorphic and four non-polymorphic STSs, as well as three
ESTs, carboxypeptidase A3 (CPA3), angiotensin II receptor gene (AGTR1) (Davies et al., 1994),
and D3S1319E, previously assigned to the proximity of the USH3 locus defined by cytogenetic
breakpoints of somatic cell hybrids (Naylor et al., 1996), were localized within the contig. We
assigned CPA3 centromeric to the marker D3S1299, and it was therefore excluded as USH3
positionally. AGTR1 was excluded by segregation analysis (Zmax = 3.12; θ = 0.08), in accordance
with its physical localization between D3S1308 and D3S1555 in the contig. Although we
localized D3S1319E centromeric to the marker D3S1299, based on the homology to profilin-2
(PFN2), and the regulatory role of profilins in actin polymerization (Theriot and Mitchison,
1993), it was considered to be a good functional candidate for USH3 (see below). Two ESTs, six
genes, and two STSs previously mapped to chromosome 3q (Naylor et al., 1996), were excluded
from the YAC contig positionally: D3S1324E, D3S1492E, cellular retinol-binding protein 1
(CRBP1), ribophorin I (RPN1), membrane metalloendopeptidase (MME), phosphatidylinositol 3-
kinase (PIK3CA) (Volinia et al., 1994), neuronally expressed EPH-related tyrosine kinase (NET)
(Tang et al., 1995), myosin light chain kinase (MLCK) (Potier et al., 1995), D3S1111, and
D3S1978.
To further refine the minimum critical USH3 interval, and to isolate additional candidate
genes, we set out to construct a physical map consisting of BAC clones between the markers
D3S1299 and D3S1279. We screened the Research Genetics Human BAC library using the STSs
previously mapped to the YAC contig or sequenced from the ends of the BAC clones. Altogether,
21 BAC clones and 28 novel STSs generated from the ends of those clones were placed on the
physical map. Two BAC clones, 282N2 and 280J1, were found to be rearranged or chimeric. As a
result, a BAC contig with one gap close to the marker D3S1299 at the centromeric end of the
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critical region was constructed. Finally, at least a five times clone coverage was obtained between
a new centromeric flanking marker 107G19CA7 (see below) and the telomeric marker D3S3625.
Initially, two BAC clones (25B8 and 545J16) were selected for screening novel CA-
repeats by hybridizing with the oligonucleotide (GT)16 as a probe. As a result, two polymorphic
markers, 25B8CA1 and 25B8CA2, were obtained from the BAC clone 25B8. After identifying
several uninformative CA-repeats, and isolating of additional BAC clones, the third microsatellite
marker, 107G19CA7, was found in the clone 107G19. The physical order of the new markers
between the flanking markers D3S1299 and D3S3625, cen-25B8CA2-25B8CA1-107G19CA7-tel,
was confirmed by STS content mapping of the BACs and supported by the results of the
haplotype analysis. Two USH3 chromosomes bearing ancestral alleles solely at two markers (see
previous results) revealed a different allele at 107G19CA7, which was thus thought to represent a
novel centromeric boundary of the USH3 locus allowing further narrowing of the critical interval
(Table 4). Based on the sizes of the BACs determined by pulsed-field electrophoresis, the USH3
critical region was approximately 250 kb bordered by the markers 107G19CA7 and D3S3625
(Figure 5.).
Table 4. Haplotypes and pexcess values associated with the USH3 locus. The conserved haplotype is boxed.
Marker p excess No. of chrs 
cen with founder allele
USH3/ctrl
D3S3661 0.79 71/25 2 2 2 2 2 2 1 2 2 2 2 2 4 2 2 2 1 1 2 2 2 2 2 2 2 2 1 1 2 2 2 2
D3S1555 0.71 64/17 3 3 3 3 3 3 3 2 1 1 1 3 2 2 3 1 1 1 3 3 3 3 3 3 3 6 3 1 1 1 3 3
D3S1308 0.69 66/22 2 2 2 2 2 2 2 2 2 2 2 1 3 3 4 3 1 4 2 2 2 3 2 2 2 2 2 2 1 1 2 2
D3S2401 0.78 69/19 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 6 1 6 8 1 1 10 1 7 7 5 5 1 1
D3S1299 0.83 69/11 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 5 5 5 2 6 6 2 3 3 5 5 6 6
25B8CA2 0.80 69/8 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 1 6 6 6 6 6 6 3 5
25B8CA1 0.95 76/8 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 6 6 5 5
107G19CA7 0.97 77/1 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 3 3 6 6
D3S3625 0.94 76/17 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 6 6
D3S1594 0.94 75/9 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 8 8
D3S1279 0.87 72/16 4 4 4 4 4 11 4 4 4 4 6 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 11 3 2 2
D3S1746 0.72 59/5 6 8 7 1 5 6 6 6 6 7 5 6 6 6 6 8 6 5 6 7 6 6 5 6 6 5 6 6 2 2 6 6
tel
No. of chrs: 79/48
USH3/ 36/  1/  5/  1/  3/  1/  1/  1/  1/  1/  1/  2/  1/  2/  1/  1/  1/  2/  1/  1/  1/  1/  1/  1/  2/  1/  2/  1/  1/  1/  2/  1/
ctrl 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
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4.2. ESTs provide probes to localize the positional USH3 candidate genes (I, II)
A nucleotide BLAST search (BLASTn) (Altschul et al., 1990) with the EST D3S1319E revealed
homologies in opposite directions of the sequence, for the ADP-ribosylation factor 1 gene and
profilin-2 (PFN2), suggesting that it represents a chimeric cDNA clone containing sequences
from two different genes. The sequence for PFN2 (GenBank accession no. L10678) had been
published (Honore et al., 1993), but the gene had not been localized previously. The PCR primers
that we used in the physical mapping of D3S1319E, were derived from the PFN2 sequences
suggesting that we had localized the gene for profilin-2 to chromosome 3q. Based on the possible
interactions of profilins with actins, PFN2 was studied as a functional candidate for USH3. A 633
bp of the PFN2 cDNA was amplified by RT-PCR from EBV-transformed lymphoblast-derived
mRNA from two USH3 patients and healthy individuals. Direct sequencing of the PCR fragments
did not reveal any changes. Later, it has been suggested that the PFN2 protein has two different
isoforms, PFN2a and PFN2b, being involved in different biochemical events, such as neural tube
development and regulation of synaptic vesicle traffic (Lambrechts et al., 2000).
Altogether seven out of fourteen ESTs derived from the Transcript Map of the Human
Genome and the Gene Map 98 of the Human Genome could be further mapped by PCR to the
BAC clones within the interval D3S1299-D3S1279. All seven ESTs, TIGRA002B48, WI-11937,
WI-11588, SHGC-133, WI-17533, KIAA0001, and D3S3882 were subjected to BLAST searches,
and four of them, WI-11588, SHGC-133, KIAA0001, and D3S3882, were found to represent two
separate genes, whose mRNA sequences were available in GenBank. These genes were
considered as potential candidate genes for USH3 and were further studied in patients.
According to BLAST searches, the ESTs WI-11588 and SHGC-133 were found to
represent the Homo sapiens seven-in-absentia (Drosophila) homolog 2 gene, SIAH2 (GenBank
accession no. NM_005067), which has been characterized in detail by Hu et al. (1997). SIAH2
was an intriguing functional candidate for USH3, as the orthologous gene seven-in-absentia
(sina) has been shown to perform an important role in the photoreceptor development of
Drosophila melanogaster; loss-of-function mutations in sina cause the R7 photoreceptor cell to
adopt a cone cell fate (Carthew and Rubin, 1990). In addition, the mouse homologue, Siah2, has
been mapped to the middle of mouse chromosome 3 (Holloway et al., 1997), close to the same
chromosomal region, on which we assigned the mouse Pfn2 gene (see below). SIAH2 containing
a 972-bp coding region plus 100 bp of the 5’- and 317 bp of the 3’-UTR was sequenced in two
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USH3 patients, two carriers and two controls from PCR amplified genomic DNA, but no
alterations were found.
The ESTs KIAA0001 and D3S3882 were found to be 5’-end sequences of the previously
described KIAA0001 mRNA (GenBank accession no. NM_014879) (Nomura et al., 1994). The
possible function of the KIAA0001 gene is unknown, although BLAST searches suggest that the
KIAA0001 mRNA sequence represents a probable ortholog of the rat VTR (ventral tegmentum
receptor) 15-20 gene. The VTR 15-20 protein is a possible cell-surface orphan G-protein-coupled
receptor expressed throughout the mammalian nervous system and in peripheral tissues including
the spleen. The possible role in neuroimmune function has been suggested, although no evidence
for ligand binding activity was found so far (Charlton et al., 1997). For mutation analysis of the
KIAA0001 gene in USH3 patients, PCR amplification and subsequent sequencing were
performed, but no relevant sequence alterations could be detected in the 1016-bp coding region
from patients' genomic DNA, while mutations in the so far uncharacterized regulatory regions
could not be excluded. Northern blot analysis, using a 1010-bp amplified product from the
KIAA0001 coding region as a probe, detected a 2.4-kb transcript highly expressed in heart and
placenta, and less in brain, lung, liver, skeletal muscle, kidney, and pancreas.
Based on our physical map, the ESTs TIGRA002B48 and WI-11937, were excluded by
location as candidates for USH3. An EST WI-17533, a positional candidate for USH3, was
thought to represent the 3'-UTR of a putative gene with no known homology. Several attempts to
isolate the full-length cDNA of the novel gene by RT-PCR and RACE PCR were performed
without success. Later, the EST was shown to reside slightly outside of the critical 250-kb region
and was not considered for further analysis.
4.3. Mouse homologue of profilin-2 (I)
In the localization of a putative mouse homologue for USH3, the EUICB mapping resource was
used to map an orthologous EST (r75057) sequence fragment to the PFN2 3'-UTR (GenBank
accession no. R75057). The EST r75057 was mapped to an approximately 5-cM region of mouse
chromosome 3 between the markers D3Mit66 and D3Mit22 by linkage and haplotype analyses.
This region was known to contain two other loci, Mme and Si-s, mapping to human chromosome
3q as well, and was thereby consistent with the localization of PFN2 in our physical map. Thus,
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we defined a putative mouse USH3 chromosomal region as a conserved segment defined by Pfn2,
Mme, and Si-s.
5. From physical map to complete DNA sequence of the USH3 region
(unpublished, III)
Initially, a BAC clone 25B8 was chosen as a target for shotgun sequencing (unpublished data).
The gaps between the genomic contigs were filled and partly connected by additional sequencing
of plasmid DNA by primer walking from the contig end sequences and by PCR across the gaps.
As a result, the genomic sequence of 148.7-kb consisting of seven contiguous sequence contigs of
sizes of 0.5 kb to 57.6 kb was assembled (unpublished data). Orientation from centromere to
telomere was confirmed by the marker order obtained from our physical map. Later, as a novel
polymorphism 107G19CA7 was obtained from BAC 107G19, and the critical USH3 region
between the markers 107G19CA7 and D3S3625 was suggested, we focused on studying the
partly overlapping BAC clones 355L4 and 545J16, which were subcloned and assembled by
methods used earlier. To extend the distal sequences, the database-derived BAC clone RP11-
385G14 (GenBank accession no. AC011103) sequence was aligned with genomic contigs of the
subcloned BAC 545J16. Eventually, a final sequence contig of 207 kb was assembled.
5.1. Full 207-kb DNA sequence allows identification of additional candidate genes
A BLASTn search of the 207-kb contig identified 30 distinct or partly overlapping human ESTs
and 11 orthologous mouse or rat ESTs. The region further contained a previously identified and
excluded gene, KIAA0001, as well as a human platelet activating receptor homolog, H963
(GenBank accession no. AF002986). A protein similarity search (BLASTx) revealed a high
sequence similarity to a human OPA-containing gene, HOPA (GenBank accession no.
AF132033) (Philibert et al., 1999), also called trinucleotide repeat-containing 11 gene, TNRC11,
or thyroid hormone receptor associated protein, TRAP230 (GenBank accession no. NM_005120)
(Ito et al., 1999). In addition, the complete sequence annotation, which was carried out using the
sequence annotation tools Genotator and NIX, predicted several exons and gene specific elements
on the 207-kb sequence contig. Exons predicted by at least two different programs were chosen
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for further analysis. After the in silico analysis of the genomic region, construction of the
predicted genes was undertaken by use of a combination of RT-PCR, RACE experiments, and
direct PCR of cDNA libraries. In this way, we were able to isolate full-length cDNAs of two
novel genes, UCRP (Usher critical region pseudogene) (GenBank accession no. AF388367) and
NOPAR (no OPA-repeat) (GenBank accession no. AF388364), as well as its alternatively spliced
transcript, NOPAR2 (GenBank accession no. AF388365).
5.1.1. Platelet activating receptor homolog, H963
As a result of BLASTn search, a cluster of four ESTs (GenBank accession nos. AA353758,
AV653286, AV653266, and BE843843) was found to represent the 5' and 3' ends of the
previously described human platelet activating receptor homolog mRNA, H963. Significant
alignments were also obtained with several mouse and rat ESTs indicating an orthologous rodent
gene for H963. Based on its position in the critical region and the possible role as a novel G-
protein-coupled receptor (Jacobs et al., 1997), H963 was selected for further analyses. Since the
entire 1,272-bp cDNA sequence of H963 was available in GenBank, we were able to determine
the genomic structure of the gene by aligning the published sequence with the genomic 207-kb
sequence. The H963 gene spans an area of 4.9 kb and is made up of three exons of which the first
two are 5' untranslated exons. We sequenced the entire coding region of H963 in USH3 patients
and controls without revealing any alterations in sequence.
5.1.2. Usher critical region pseudogene, UCRP
Two novel ESTs (GenBank accession nos. R79610 and R79611) were found to represent the
same cDNA clone (IMAGE no. 146349) and partly overlap another cDNA clone (IMAGE no.
60197) with two additional ESTs (GenBank accession nos. T40442 and T39157). The latter was
contaminated by phage sequences and was not further analyzed. The full length 2,081 bp cDNA
of the novel gene, Usher critical region pseudogene (UCRP), was identified by RT-PCR from
human placenta cDNA by bridging the predicted exons in the vicinity of the EST R79611, and by
RACE PCR from Human Marathon Ready Retina cDNA library. Although the ESTs R79610 and
R79611 were derived from the 5' and 3' end of the same cDNA IMAGE clone, we were not able
to amplify the EST R79610 from neither placenta cDNA nor retina cDNA library by RT-PCR,
suggesting a genomic contamination in the clone. We further examined the expression pattern of
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UCRP by hybridizing multitissue northern blots with different UCRP cDNA fragments. A single
transcript of approximately 2.0 kb was expressed in all the tissues examined (unpublished data).
Sequence alignments revealed that the UCRP cDNA consists of five exons spanning over 70-kb
genomic DNA. However, the ORF is disrupted and thus the gene is probably an unprocessed
pseudogene. Despite this assumption, the entire gene was examined by direct sequencing from
USH3 patient and control DNA samples. The analyses did not reveal any differences between the
samples. Furthermore, the expression pattern of USH3 patients' lymphoblast derived total RNA
was normal compared to controls examined by northern blot (unpublished data).
5.1.3. No OPA-repeat gene, NOPAR
The BLASTx similarities of the 207-kb deduced amino acid sequence to the amino acid sequence
of HOPA/TRAP230 prompted further analysis of a putative homologous gene in the USH3
region. A chimeric cDNA clone (IMAGE no. 1565326) representing an EST AA931311 showed
homology to HOPA, and was thought to contain part of the 3'-UTR region of the novel putative
gene. Finally, two alternatively spliced transcripts, NOPAR and NOPAR2, were amplified by RT-
PCR from human placenta cDNA and Marathon Ready Human Retina cDNA library by bridging
the predicted exons until the 3'-UTR sequences contained in the IMAGE cDNA clone. To find
out whether some sequences at the 5'-UTR were still unidentified, primer pairs were placed
randomly upstream from the first identified ATG codon in the genomic sequence of the gene, and
PCR was performed to the predicted exon 2. This resulted in the refining of two complete cDNAs
with ORFs of 2,163 bp and 2,268 bp encoding putative polypeptide isoforms of 721 and 756
amino acids. NOPAR2  comprised an additional exon 13b between exons 13 and 14. By
comparing the genomic contig sequence with the cDNA sequences, the exon-intron boundaries
were confirmed and shown to follow the GT-AG splicing rule. Exon 1 contains the first in-frame
ATG codon in accordance with the Kozak consensus motif (Kozak, 1987), while the first stop
codon TAA is in exon 14. No splice acceptor was found at the 5' end of exon 1, suggesting this
exon to be the first. An in-frame polyadenylation signal was found 158 bp downstream from the
first termination codon and was confirmed by RT-PCR from exon 13 to the end of the signal. The
NOPAR gene spans an area of 120 kb determined by aligning the cDNA sequence with the
genomic 207-kb sequence.
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Promoter analysis using Neural Network Promoter Input programs predicted three
possible promoters for the gene. Using various coding and 5'-UTR sequences as probes in
northern analysis, abundant levels of different transcripts of sizes of 1.0 kb to 7.5 kb, and a
widespread expression pattern were detected in all 16 adult tissues tested (unpublished data). It is
highly likely that these different fragments represent differentially spliced or related transcripts
found in human tissues. No changes in expression level or in the sizes of the transcripts compared
to controls were detected, as the expression pattern of USH3 patients' lymphoblast derived total
RNA or poly(A) RNA was analyzed.
NOPAR shows 61% amino acid similarity to the amino terminus of HOPA, however, it is
only 1/3 the length of HOPA and does not contain a 3’OPA-repeat. HOPA contains two
overlapping ligand-dependent nuclear hormone receptor recognition motifs near the amino
terminus, and a highly glutamine-rich C-terminal region that results from the CAG-trinucleotide
repeats, namely an OPA (opposite paired)-motif (Philibert et al., 1999). OPA-repeats have
multiple possible functions depending on the location of the repeat in the gene, such as mediating
protein-protein interactions (Stott et al., 1995), or regulating gene expression (Feng et al., 1995;
Otten and Tapscott, 1995). The HOPA gene has been described by Nagase et al. (1996), and
assigned to chromosome Xq13 (Philibert et al., 1998). It has also been cloned by Ito et al. (1999),
as a 230-kD subunit of thyroid hormone receptor associated protein complex (TRAP) having a
widespread expression pattern. The exact role of HOPA/TRAP230 is still unknown, but it has a
possible role in thyroid hormone receptor function (Ito et al., 1999). An association with mental
retardation has been suggested (Philibert et al., 1998), as well. Thyroid hormone receptor-β  (TR-
β) has been shown to have an essential role in the development of auditory and visual systems
(Ng et al., 2001; Rüsch et al., 1998). Congenital thyroid disorders impair hearing, and
hypothyroidism in mice and rats causes deformities in the organ of Corti. Rüsch et al. (1998)
identified a defect in inner hair cells (IHC) of the organ Corti in TRβ−/− mice indicating that a TR-
mediated transcriptional pathway is required for the physiological differentiation of IHCs by the
control of genes encoding ion channels. In embryonic retina, TR is expressed on the outer nuclear
layer, being required for the development of green cone photoreceptors. Mutations in the gene
may be associated with human cone disorders (Ng et al., 2001).
Genomic sequencing of NOPAR and its alternatively spliced exon 13b indicated no
disease causing mutations in patients' DNA, while two novel single nucleotide polymorphisms,
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RSNP2 and TSNP1, were detected within its introns. Thus RSNP2 and TSNP1 were localized
between markers 107G19CA7 and D3S3625; TSNP1 was telomeric to RSNP2. A haplotype
analysis revealed conservation of the segment RSNP2-TSNP1 in all of the 48 USH3
chromosomes studied. This supported the previous haplotype analysis placing USH3 telomeric to
107G19CA7. However, a recombination event in the same USH3 family, which was previously
used to refine the site of the USH3 mutation telomeric to 107G19CA7, excluded the RSNP2-
TSNP1-D3S3625-tel segment as the site of the causative mutation, restricting the disease locus to
a 60-kb region between markers 107G19CA7 and RSNP2 (Figure 4).
Figure 4. Refined mapping of the USH3 locus between markers 107G19CA7 and RSNP2. The isolated genes
(arrows) UCRP (Usher critical region pseudogene), NOPAR (No OPA-repeat gene), H963, and KIAA0001, as well
as ESTs (white flags) are shown below the 207-kb contig. The question mark indicates the possibility for the USH3
mutation to lie in the extended 133-kb interval between markers 25B8CA2 and 107G19CA7 (see results). Database-
derived BAC clone RP11-251C9 is indicated with a striped box. Polymorphic markers are indicated with grey flags.
D3S1279USH3
CA7
D3S3625
207-kb contig
D3S1299
H963
KIAA0001
R79611
UCRP
AA931311
NOPAR
TSNP1USH3
CA2
133-kb
RP11-251C9
60 kb
250 kb
RSNP2
69
6. Identification of the USH3 gene (III)
As no additional transcripts in the remaining 60-kb critical region between markers 107G19CA7
and RSNP2 were found, and the centromeric border of the critical interval at 107G19CA7 was
suggested based on an assumed historical recombination observed in two disease associated
chromosomes only, we considered a possibility of these two haplotypes representing another,
non-founder mutation, and the common short haplotype would be a result of common alleles
present in this chromosome by chance. This prompted us to extend the sequence analysis
centromeric to 107G19CA7, towards 25B8CA2, which was conserved in 69/79 USH3
chromosomes, thus suggesting a more reliable historical recombination breakpoint (Table 4).
Similarity searches using the two assembled 148.7-kb and 207-kb contig sequences
against HTGS and GSS databases at NCBI revealed a BAC clone RP11-251C9 (GenBank
accession no. AC020636) sequences between markers 25B8CA2 and 107G19CA7. A new 133-
kb contig was constructed by aligning RP11-251C9 sequences with the contigs (Figure 5), and a
subsequent BLASTn analysis revealed 11 novel ESTs without any homology to known cDNAs
or genes. Since one EST, 35f2 (GenBank accession no. W27577), was found to be retina-derived
based on the database information, and the sequence annotation software NIX placed several
exons in the vicinity of this EST (Figure 6), we performed interexon PCR in order to obtain a
full-length cDNA. RT-PCR from human retina-derived total RNA preparations detected two
different USH3 transcripts. The obtained USH3 cDNA is 1,444 bp in length, with a 5'-UTR of at
least 392 bp and a 692-bp 3'-UTR (Figure 7A). The 360-bp open reading frame encodes a
putative polypeptide of 120 amino acids with a calculated molecular mass of 13.4 kD, and
comprises four exons. A splice variant, USH3 gene_b, comprises an additional 87-bp exon (1b)
with an inframe stop codon between exons 1 and 2. The first in-frame ATG codon in exon 1
conforms to the Kozak motif (Kozak, 1987). Computational promoter analysis revealed five
possible promoters for the gene. The putative promoter of USH3 lacks TATA boxes, but has GC
and CAAT boxes, which are usually strong determinants of promoter efficiency. Three
alternative polyadenylation signals were found at 156 bp, 764 bp, and 3,568 bp downstream from
the termination codon, consistent with the northern blot analysis indicating three transcripts of
different sizes.
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6.1. USH3 mutation analyses
The USH3 gene was screened for mutations by PCR-amplification of the genomic fragments in
patients' DNA, followed by SSCP analysis and/or sequencing. We identified three causative
mutations in Finnish and Italian USH3 patients in exons 2 and 3. The Finnish founder mutation,
Finmajor (Y100X), is a nonsense mutation c.300T>G at codon 100 in exon 3, and was found in
homozygous form in 52 USH3 patients being responsible for 94% of the USH3 patients studied.
All 36 parents analyzed and 26 out of 45 unaffected siblings were heterozygous for the mutation.
In two families, one parent was affected and homozygous for the mutation. The second Finnish
mutation, Finminor (M44K), is a c.131T>A transversion at codon 44 in exon 2 resulting in an
amino acid substitution of lysine for methionine. It was found in a heterozygous form in four
patients in two Finnish families. These patients have inherited the common ancestral haplotype
from one parent, and a partly distinctive haplotype from the other parent, being compound
heterozygous for both mutations. No homozygous patient for Finminor has been found so far. Both
Finnish mutations originate from the same region in the late settlement area (new Finland) where
USH3 is known to be prevalent (Figure 8), strongly supporting the hypothesis that the mutations
are introduced into the population after the 1500s (Norio et al., 1973; de la Chapelle, 1993).
Furthermore, the ancestral haplotype shares a long, over 6.5-cM genetic interval which strongly
indicates the founding of the Finmajor of about 20 generations ago. All the analyzed Finnish USH3
patients had a mutation in both alleles. Among 200 anonymous blood donors, one control from
the high prevalence region was heterozygous for Finmajor, giving a carrier frequency of 1:200 in
Finland. In addition to these Finnish mutations, a 3-bp deletion, c.231-233delATT, leading to the
substitution of one methionine for isoleucine and leucine at codons 77 and 78 in exon 3, was
identified in an Italian family. These results strongly suggest that the observed gene defects
underlie USH3. So far, no mutations were detected in the other non-Finnish families and patients
included in the study.
All the USH3 mutations alter the coding sequence of the gene, and there are possible
consequences for the USH3 gene expression for these mutations. The founder mutation producing
the premature stop codon could trigger the nonsense-mediated mRNA decay (NMD), in which
mRNA carrying a premature stop codon is rapidly degraded in vivo (Hentze and Kulozik, 1999),
thus preventing the synthesis of the corresponding protein. Alternatively, the mutation could
produce a truncated polypeptide. How the twenty-one aminoacid truncation affects the function
73
of the protein is difficult to predict. Most likely, it affects the stability and the structure of the
protein, or its possible interactions and assembly with other proteins. The second Finnish USH3
mutation results in a substitution of a charged polar amino acid lysine for a nonpolar amino acid
methionine which most likely affects the secondary structure of the protein. Probably, the Italian
mutation, which occurs in the predicted transmembrane domain, leads to abnormal folding of the
USH3 protein.
6.2. USH3 protein prediction and expression analyses
The USH3 open reading frame predicts a protein with no homology to any known genes so far.
Prediction of membrane topology reveals that the USH3 protein contains two potential
transmembrane helices, separating one extracellular loop, at amino acid positions 25 to 41 (inside
to outside helix) and 63 to 79 (outside to inside helix), N-terminus being inside (Figure 7B). The
N-terminal residues of the USH3 protein do not exhibit characteristics of a signal peptide, instead
a weak endoplasmic reticulum-like (ER) signal for ER retention exists in the C-terminus.
Northern blot analysis of a variety of human tissues utilizing the USH3 cDNA as a probe detected
transcripts of approximately 4.5 kb, 1.5 kb, and 1.0 kb. Three signals could correspond to
transcripts with alternative splicing in the 3'-UTR region recognized by different poly(A) sites or
differentially spliced exons. From the tissues studied, only human lymphoblasts did not show a
signal, as confirmed both by RT-PCR and northern blotting. In situ hybridization, using in vitro
transcribed 35S-labelled antisense and control-sense mouse USH3 cRNA probes detected a low-
level, ubiquitous expression in mouse retinal and cochlear tissues.
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Figure 7. Predicted schematic structure of the USH3 gene and protein. A. The four exons are depicted by numbered
boxes. The sizes of the exons are shown below the boxes and those of the three separating introns above the lines.
The translation initiation site, and the first stop codon are indicated. Three polyadenylation signals and their
predicted locations downstream of the termination codon are indicated by arrows. The alternatively spliced exon 1b
(E1b) is indicated. B. The USH3 protein is predicted to contain two transmembrane helices. The locations of Finmajor
(Y100X), Finminor (M44K), and Italian c.231-233delATT mutations in the protein are indicated with an arrow.
Figure 8. A pedigree of a Finnish USH3 family segregating a paternal Finmajor (c.300T>G) mutation and a maternal
Finminor (c.131T>A) mutation. The chromosome assumed to carry the disease allele is typed in bold and boxed. A
recombination in the maternal chromosome of individual II-1 excludes the segment RSNP2-D3S1279 as the site of
the USH3 mutation. The map of Finland shows the parental birthplaces of USH3 patients. The birthplaces of the two
mothers carrying the Finminor mutation are indicated with circles.
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6.4. A mouse homologue for USH3 (III, unpublished)
Alignment of the USH3 gene ORF with Celera Assembled and Annotated Mouse Genome
databases indicated several genomic fragments highly homologous to the exons 2 and 3 of the
gene. The mouse Marathon Ready Retina cDNA was PCR-amplified with primers homologous to
the USH3 coding region, producing a fragment of 262 bp. Subsequent sequencing indicated that
this fragment is highly conserved at nucleotide level between mouse and human (87% identity)
(unpublished results). The efforts to identify the full-length cDNA by RT-PCR or RACE PCR
have not yet been successful. The mouse multi-tissue northern blot hybridization with the 262-bp
fragment detects a 2.0-kb transcript in all tissues examined (heart, brain, spleen, lung, liver,
skeletal muscle, and testis). In addition, a weak 1.0-kb transcript in all tissues examined as well as
a 4.0-kb transcript in heart and liver were detected (unpublished data) (Figure 9).
Figure 9. Mouse ush3 gene expression. Northern analysis of a mouse multiple-tissue blot was performed using a
probe homologous to the coding region of the human USH3 gene. Two signals of approximately 2.0 kb and 1.0 kb
are detected in all tissues tested. In addition, a weak signal of 4.0 kb is detected in heart and liver mRNA.
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CONCLUSIONS AND FUTURE PROSPECTS
This study describes the positional cloning of the USH3 gene which was initiated after the
assignment of the USH3 locus to chromosome 3q21-q25 by genome-wide linkage mapping in
Finnish USH3 families representing progressive hearing loss, retinitis pigmentosa, and variable
vestibular dysfunction (Sankila et al., 1995). The molecular analyses, including linkage, linkage
disequilibrium, and physical mapping, aided us to refine the USH3 locus from 5-cM to a 250-kb
region. Thereafter, the genomic contigs were constructed by shotgun sequencing, and mutation
analyses of several in silico positional candidate genes, as well as an additional sequence analysis
of an extended 133-kb genomic region, were needed until the candidate for USH3 was identified.
Identification of three different USH3 mutations in Finnish and Italian patients provided evidence
for this particular gene to underlie the disease. Based on the mutation results and the earlier
clinical data (Pakarinen et al., 1995b; Pakarinen et al., 1996; Pakarinen 1997), no correlation
between different USH3 mutations and patients' phenotypes were observed. Effects of putative
modifier genes at different loci could explain the phenotype differences among the USH3
patients.
Using traditional experimental methods in the transcript isolation is usually time-
consuming and laborious. The release of the whole genome sequence combined with the
sequence annotation data by the Human Sequencing Consortium allows novel approaches to gene
identification, further facilitating the process of positional cloning by "virtual cloning". In this
study, the progress from genetic localization of USH3, defined by linkage disequilibrium and
haplotype analyses, to the identification of the disease gene was accelerated significantly with the
resources of the large-scale genomic sequencing data, which we had produced, and the human
genome working draft. Several gene prediction programs were used, which enabled us to analyze
the genomic contigs through the similarity searches against databases of well-characterized
genes, ESTs, and proteins, as well as to predict genes in a given raw DNA sequence by defining
their splicing patterns. Systematic PCR amplification of retina cDNA using primers spanning
genes of interest, and sequencing of the PCR products confirmed the discovery of a novel gene.
The USH3 gene is ubiquitously expressed, but probably only the retina and the cochlea
are affected by the inherited mutations. USH3 being a novel gene with no homology to any
known genes or proteins provides limited information about the possible molecular pathways of
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the disease, and further studies in the wider contex, defining the specific function and the
localization of the USH3 protein, are needed. Functional tests in vitro, such as different antibody
labelling and detection systems using cultured cells or cell extracts, can show how mutations in
the USH3  gene affect its expression and function. While cultured transfected cells give
information about the gene expression and subcellular localization, only tests in vivo using animal
models in gene targeting, such as mice homozygous for a targeted deletion of the USH3 gene or
natural animal models of the disease, should lead to a better understanding of the functional
consequences of the defective USH3. A yeast two-hybrid screen could provide some clues about
the molecular interactions between different proteins and identify other genes that may be
involved in the disease. The resulting information of the biological processes involved in the
normal and pathogenic states can be finally used to design new gene therapies.
Individuals with USH3 have a progressive loss of hearing and vision. The severity of the
hearing loss and the degree of its progression are variable complicating the confirmation of the
diagnosis. Therefore, knowledge about the mutated gene provides improvements in the accuracy
of presymptomatic diagnosis, especially in children with late onset hearing loss, and in carrier
identification. It is also important in genetic counseling of the families, and might prove helpful
for example in making educational choices.
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